Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 1 of 51  
SAFETY  AND FEASIBILITY  OF CULTIVATED AUTOLOGOUS LIMBAL EPITHELIAL CELL 
TRANSPLANTATION IN THE TREATMENT OF LIMBAL STEM CELL DEFICIENCY  
 
Protocol #: 14-124H  
FDA IND #: 16102  
Phase: I/II 
Version and Date:  
6.0 02/3/2022  
 
Principal Investigator and Enrolling Site:  
Ula Jurkunas, M D 
Massachusetts Eye and Ear Infirmary  
243 Charles Street  
Boston, MA 02114 
 
Co-Investigator:  
Reza Dana, M D, MPH, MSc  
Massachusetts Eye and Ear Infirmary  
243 Charles Street  
Boston, MA 02114 
 
Jia Yin, MD, PhD  
Massachusetts Eye and Ear Infirmary  
243 Charles Street  
Boston, MA 02114 
 
Collaborators : 
Jerome Ritz, M D 
Connell and O’Reilly Families  
Cell Manipulation Core Facility  
450 Brookline Ave  
Boston, MA 02215 
 
Allison Ayala , MS 
Jaeb Center for Health Research  
15310 Amberly Drive Ste 350  
Tampa, FL 33647  
 
Myriam Armant, PhD  
TransLab 
61 Binney Street  
208 Enders Building  
Boston, MA 02115 
 
 Funding Support:  
NIH/NEI through UG1 grant s 
UG1EY026508 (Massachusetts Eye and Ear Infirmary)  
UG1EY027726 (Cell Manipulation Core Facility)  
UG1EY027725 (Coordinating Center)  
 
Past Funding Support:  
Production Assistance for Cellular Therapies (PACT)  
 of the National Heart, Lung,  and Blood Institute  
National Institutes of Health  
Curing Kids Fund  
Massachusetts Lions Eye Research Foundation  

Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 2 of 51 List of Abbreviations  
 
AE  Adverse Event  
AIDS   Acquired Immune Deficiency Syndrome  
AMT   Amniotic Membrane Transplantation  
AS-OCT   Anterior Segment Optical Coherence Tomography  
BCVA   Best Corrected V isual Acuity  
BUN   Blood, Urea, Nitrogen  
CALEC   Cultivated Autologous Limbal Epithelial Cells  
CLAU   Conjunctival Limbal Autograft  
CMCF   Cell Manipulation Core Facility  
CRF  Case Report Form  
eCRF   Electronic Case Report Form  
DFCI   Dana- Farber Cancer Institute  
eGFR    Estimated Glomerular Filtration Rate  
FDA  Food and Drug Administration 
GA  General Anesthesia  
HIPAA  Health Insurance Portability and Accountability Act  
HIV  Human Immunodeficiency Virus  
ICF  Informed Consent Form  
IND  Investigational New Drug  
IRB  Institutional Review Board 
IVCM   In Vivo Confocal Microscopy  
LSC  Limbal Stem Cells  
LSCD   Limbal Stem Cell Deficiency  
MEEI   Massachusetts Eye and Ear Infirmary  
MIVA   Monitored Intravenous Anesthesia  
MM  Medical Monitor  
MOP   Manual of Procedures  
MRSA   Methicillin -resistant Staphylococcus aureus  
NEI  National Eye Institute  
OSDI   Ocular Surface Disease Index  
PACT   Production Assistance for Cellular Therapies  
PHRC   Partners Human Research Committee  
QC  Quality Control  
SANDE   Symptom Assessment i N Dry Eye  
SOP  Standard Operating Procedures  
 
 
 
  
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 3 of 51  
Contents  
1. BACKGROUND  ..................................................................................................................... 6 
2. STUDY AIMS  ......................................................................................................................... 9 
2.1. Primary Objectives  .................................................................................................. 9 
2.2. Secondary Objectives  .............................................................................................. 9 
2.3. Study Conclusions  ................................................................................................... 9 
3. STUDY TIMELINE  ................................................................................................................10 
4. STUDY ORGANIZATION .....................................................................................................11 
5. POPULATION AND RECRUITMENT  ...................................................................................12 
5.1. Participant Inclusion Criteria  ...................................................................................12 
5.2. Participant Exclusion Criteria  ..................................................................................12 
5.2.1. General Exclusion Criteria  ...................................................................................12 
5.2.2. Exclusion Based on Either Eye  ............................................................................13 
5.2.3. Exclusion Based on Donor Eye  ...........................................................................13 
5.2.4. Exclusion Based on Recipient Eye  ......................................................................13 
5.3. Recruitment  ............................................................................................................13 
5.4. Informed Consent Process  .....................................................................................13 
5.5. Enrollment Procedures  ...........................................................................................14 
5.6. Second Biopsy ........................................................................................................15 
5.7. Discontinuation of Study Follow Up And Participants Who Do Not Complete a 
Transplant  .....................................................................................................................15 
5.8. Termination of Study ...............................................................................................16 
6. STUDY PROCEDURES, MEASUREMENTS, AND VISIT SCHEDULE  ................................17 
6.1. CALEC Manufacturing ............................................................................................ 17 
6.2. Preparation and Administration of Study Treatments  ..............................................17 
6.2.1. Preparation (CALEC)  ...........................................................................................17 
6.2.1.1. Limbal Biopsy  ...................................................................................................17 
6.2.1.2. Transplantation  ................................................................................................. 17 
6.2.2. Administration  ......................................................................................................17 
6.2.2.1. CALEC Procedure –  Biopsy  ..............................................................................17 
6.2.2.2. CALEC Procedure –  Transplantation  ................................................................18 
6.3. Modification of Study Intervention for a Participant  .................................................18  
6.4. Additional Surgeries  ...............................................................................................19 
6.5. Medications and Treatments  ...................................................................................19 
6.5.1. Concomitant Medication/Treatments  ...................................................................19 
6.5.2. Acceptable Concomitant Medications  ..................................................................19 
6.5.3. Prohibited Concomitant Medications  ....................................................................19 
6.5.4. Study Medication Regimen ..................................................................................19 
6.5.5. Other Treatments  ................................................................................................20 
6.6. Clinical Evaluations  ................................................................................................20 
6.6.1. Symptom Assessment  .........................................................................................21 
6.6.1.1. Ocular Surface Disease Index (OSDI)  ..............................................................21 
6.6.1.2. Symptom Assessment iN Dry Eye (SANDE)  .....................................................21 
6.6.2. Visual Acuity  ........................................................................................................21 
6.6.3. Intraocular Pressure (IOP) Evaluation ................................................................. 21 
6.6.4. Slit Lamp Examination .........................................................................................21 
6.6.4.1. Corneal Opacification .......................................................................................22 
6.6.4.2. Corneal Fluorescein Staining ............................................................................22 
6.6.5. Schirmer’s Test  ....................................................................................................22 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 4 of 51 6.6.6. Impression Cytology  ............................................................................................ 22 
6.6.7. Slit Lamp Photography  ........................................................................................22 
6.6.7.1. Photography for Neovascular Area  ................................................................... 22 
6.6.7.2. Photography for Epithelial Defect Area  .............................................................23 
6.6.8. Lid Margin and Conjunctiva Cultures  ................................................................... 23 
6.6.9. Fundus Examination ............................................................................................ 23 
6.7. Laboratory Evaluations  ...........................................................................................24 
6.8. Study Schedule ......................................................................................................24 
6.8.1. Study Screening ..................................................................................................25 
6.8.2. Baseline (Within 30 days of Screening Visit)  ........................................................26 
6.8.3. Limbal Biopsy (Within 25 Days of Baseline VISIT)  ...............................................27 
6.8.4. Transportation of Tissue to CMCF & Preparation of CALEC  ................................27 
6.8.5. Post -Biopsy Assessment of Donor Eye (1- 2 Days after CALEC Biopsy)  .............. 27 
6.8.6. Transportation of CALEC from CMCF to MEEI  ....................................................27 
6.8.7. Preoperative Assessment of Recipient Eye (1 to 5 Days Prior to Transplant)  ......27 
6.8.8. Corneal Reconstruction with CALEC (Day 0)  .......................................................27 
6.8.9. Follow -up Period ..................................................................................................28 
6.8.10. Post -Transplant (Day 1)  .....................................................................................28 
6.8.11. Post -Op Follow -up: Weeks 1, 2, Month 1 (4 WEEKS ± 3 days) and Months 3, 6, 
9, 12 (13, 26, 39, 52 WEEKS ± 1 week), and Months 15, and 18 (65 and 78 WEEKS ±2 
weeks)  ...........................................................................................................................28 
6.8.12. Early Termination Visit  .......................................................................................29 
6.8.13. Unscheduled Visit  ..............................................................................................29 
7. OUTCOME MEASURES .......................................................................................................30 
7.1. Primary Outcome Measures  ...................................................................................30 
7.1.1. Safety Measures  ..................................................................................................30 
7.1.2. Feasibility Measures  ............................................................................................ 30 
7.2. Secondary Outcome Measures  ..............................................................................30 
7.3. Other Outcome Measures  ......................................................................................31 
8. MONITORING STUDY PROGRESS  .....................................................................................32 
9. ASSESSMENT OF SAFETY  ................................................................................................33 
9.1. Methods and Timing for Assessing, Recording, and Reporting of Safety Parameters ......................................................................................................................................33 
9.2. Safety Oversight  .....................................................................................................33 
9.3. Study Halting Guidelines  ........................................................................................33 
10. MONITORING PROTOCOL ADHERENCE  ........................................................................35
 
11. QUALITY CONTROL OF DATA .........................................................................................36 
12. CONTINUED FOLLOW UP FOR CLAU PARTICIPANT ENROLLED PRIOR TO PROTOCOL AMENDMENT DISCONTINUING CLAU ARM OBJECTIVE  ................................37 
13. LITERATURE REFERENCES  ............................................................................................ 38 
14. APPENDICES .....................................................................................................................41 
14.1. APPENDIX I: Symptom Measurement Scales  ......................................................41 
14.2. APPENDIX II: National Eye Institute Corneal Fluorescein Grading Scale .............44 
14.3. APPENDIX III: Vascularization Measurement Tool  ...............................................45 
14.4. APPENDIX IV: Fantes Scale for Corneal Opacity  .................................................46 
14.5. APPENDIX V: Impression Cytology  ......................................................................47 
14.6. APPENDIX VI: Schedules of Events & Procedures For Participants Completing 
Transplant  .....................................................................................................................48 
15. PROTOCOL ADDENDUM: SECOND TRANSPLANT  ........................................................49 
15.1. OVERVIEW  ..........................................................................................................49 
15.2. CRITERIA FOR SECOND TRANSPLANT  ............................................................49 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 5 of 51 15.3. INFORMED CONSENT PROCESS  ......................................................................49 
15.4. SCREENING AND BASELINE .............................................................................49 
15.5. BIOPSY AND TRANSPLANT  ...............................................................................50 
15.6. STUDY PROCEDURES, MEASUREMENTS, AND VISIT SCHEDULE  ................51 
15.7. ANALYSIS CONSIDERATIONS ...........................................................................51 
15.7.1. SAFETY  ............................................................................................................51 
15.7.2. FEASIBILITY  .....................................................................................................51 
15.7.3. EFFICACY  .........................................................................................................51 
 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 6 of 51 1. BACKGROUND  1 
The cornea is a transparent, avascular tissue covered by non- keratinized stratified epithelium 2 
that is responsible for maintaining a smooth ocular surface for normal vision as well as for 3 
providing a barrier against environmental  and external  stress. The entire ocular surface is 4 
covered by corneal, limbal, and conjunctival epithelial cells that, together with a stable pre - 5 
ocular tear film, maintain its integrity.   6 
 7 
Corneal epithelial stem cells are adult somatic stem cells located at the limbus  and represent 8 
the ultimate source of  transparent corneal epithelium  (Schermer et al., 1986, Tseng et al., 9 
1996) . When these limbal stem cells  (LSC)  become dysfunctional or def icient,  the cornea is 10 
unable to maintain its surface epithelial integrity and phenotype and a disease called corneal 11 
limbal stem cell d eficiency (LSCD) develops.  12 
 13 
Corneal scarring and opacity is the 5th commonest cause of blindness worldwide, accounting for 14 
5.1% of blindness ( Resnikoff et al., 2008 ). LSCD,  a major cause of corneal scarring, arises from 15 
a variety of congenital or acquired causes that are infectious (like trachoma), immunologic, 16 
oncologic or iatrogenic in nature and in turn lead to severe ocular surface dysfunction. The 17 
LSCD can be caused by Stevens -Johnson syndrome, ocular cicatricial pemphi goid, aniridia, 18 
chemical or thermal burns, contact lenses, a variety of microbial infections, long- term use of 19 
topical (including antiglaucoma)  medications, irradiation, tumors, or multiple surgical procedures 20 
or cryotherapy involving the ocular surface. LSCD afflicts thousands of people in North America 21 
(Holland and Schwartz, 1999)  and is particularly prevalent in chemical and thermal burns  of the 22 
ocular surface .  23 
 24 
The clinical hallmark of LSCD is conjunctivalization of the corneal surface (or replacement of 25 
normal  and transparent  corneal epithelium by opaque conjunc tival epithelium ), 26 
neovascularization, recurrent or persistent epithelial defects, ocular surface inflammation, and 27 
scarring all of which can  lead to decreased vision, pain, and impaired quality of life 28 
(Puangsricharern and Tseng, 1995 ) (Kruse et al., 1990)  (Figure 1). 29 
 30 
 
 
  31 
Figure 1 A and B: In limbal stem cell deficiency (LSCD), the cornea becomes vascularized, 32 
scarred, and opaque; the demarcation between cornea and conjunctiva is lost. Patients 33 
experience loss of vision, photophobia, irritation and pain.  34 
Conventional  corneal transplantation replaces only central cornea and  cannot satisfactorily treat 35 
the corneal surface with extensive or complete LSCD. As a result, therapeutic strategies have 36 
been developed at replacing limbal epithelium  with or without corneal transplantation surgery 37 
(Tseng, 1996, Kenyon and Tseng, 1989, Copeland and Char, 1990, Morgan and Murray, 1996 , 38 
Holland and Schwartz, 1996) . Several techniques have been reported for limbal stem c ell 39 
transplantation or keratoepithelioplasty. In unilateral cases of LSCD, donor tissue is  obtained 40 

Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 7 of 51 from the fellow eye, called limbal autograft ; in bilateral cases of LSCD  tissue is obtained from 41 
cadaver donor s, called limbal allograft  (Yalcindag et al., 2008, Dua and Azuara- Blanco, 1999, 42 
Kenyon and Tseng, 1989) . Both procedures seek to provide therapeutic benefit through  43 
transplantation of a new source of epithelium onto  a diseased ocular surface after the removal 44 
of the recipient’s  scarred  and diseased  epithelium (Dua and Forrester, 1990, Dua and Azuara- 45 
Blanco, 1999, Clinch et al., 1992 , Jenkins et al., 1993, Kenyon and Tseng, 1989) . Since limbus 46 
is vascularized and contains antigen presenting cells, limbal allografts carry a high risk of 47 
rejection and require use of lifelong systemic  immun osuppression. Limbal allograft survival is 48 
limited to 50% at 5 years despite the use of systemic  immunosuppression and survival is much 49 
lower if concurrent penetrating keratoplasty is performed to aid in visual rehabilitation ( Smolin, 50 
2005) . 51 
 52 
Autologous limbal transplantation, such as conjunctival limbal autograft (CLAU), is a viable 53 
option in unilateral cases and it circumvents the use of immunosuppression.  Traditionally, two 54 
large pieces of the limbus are removed from the donor eye. T he main limitation of this technique 55 
is that it carries risks of inducing limbal stem cell deficiency to the donor eye when harvesting 56 
limbal autografts ( Haamann et al., 1998, Tan et al., 1996 , Kenyon and Tseng, 1989 ). Cases of 57 
corneal haze, pseudopterygium, epithelial defects and conjunctivalization in the donor eye have 58 
been reported (Dua et al., 2010 , Morgan and Murray, 1996 , Fogla and Padmanabhan, 2005, 59 
Yao et al., 2002) . Although recently some attempts have been made to use a smaller graft, such 60 
as Simple Limbal Epithelial Transplantation (SLET), there are only limited data, especially 61 
regarding long- term follow -up on the new procedure (Sangwan, 2012).  62 
 63 
In order to circumvent risks of allograft rejection (as seen in limbal allografts) and damage to the 64 
donor eye (as seen in limbal autografts , such as CLAU ), a technique has been developed to 65 
cultivate  autologous  limbal epithelial cells (CALEC)  for transplantation. This technique is 66 
advantageous because of its  ability to utilize a small amount of the participant ’s own tissue. The 67 
risk of damage to the donor eye is bypassed by expanding limbal epithelial (stem) cells from a 68 
small biopsy (2- 3 mm2) onto the substrate, such as amniotic membrane, in culture before 69 
transplantation. The success of using such a new surgical approach has been reported in 70 
several human studies (Koizumi et al., 2001, Rama et al., 2010, Sangwan et al., 2005, Schwab 71 
et al., 2000 , Shimazaki et al., 2007 , Shortt et al., 2007, Basu et al., 2012 , Baradaran- Rafii et al., 72 
2010, Nakamura et al., 2006, Pellegrini et al., 1997) .  73 
 74 
The general advantages of CALEC transplantation are that 1) it provides an amplified source of 75 
epithelial (stem) cells as compared to transplantation of the similar size of limbal biopsy, 2) it is 76 
an autologous source of cells and does not carry risk of immunologic rejection, 3) it carries 77 
significantly lower risk of inducing LSCD in the donor eye, and 4) it is possible to repeat the 78 
biopsy and transplant owing to the non-invasiveness of the procedures  to both donor and 79 
recipient eyes. Currently  there are no good options for  treatment of LSCD in the U.S  and 80 
patients have a significant  burden from the  disease.  That, along with recent advances in stem 81 
cell research provide compelling   reasons  for conducting a study aimed at assessing first, the 82 
safety  and feasibility of CALEC grafts, and  additionally , their  effectiveness in treating LSCD . 83 
 84 
The most common substrate utilized for ex vivo expansion of limbal epithelial cells has been 85 
amniotic membrane. Amniotic membrane t ransplantation (AMT) has extensive history in ocular 86 
surface reconstructive surgery and its utility alone or in combination with limbal stem cell 87 
transplantation has been reported ( Holland and Schwartz, 2000 , Koizumi et al., 2000 , Kolli et 88 
al., 2010 , Nakamura et al., 2003 , Prabhasawat et al., 2001 , Shimazaki et al., 2002 ). In cases of 89 
partial LSCD, AMT alone has been shown to provide a useful substrate for regeneration of the 90 
remaining epithelial cells by enhancing epithelial cell migration and creating a hospitable 91 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 8 of 51 microenvironment mimicking limbal stem cell niche (Grueterich et al., 2003 , Tseng, 1989 , 92 
Dietrich -Ntoukas et al., 2012, Shahdadfar et al., 2012, Tsai and Tsai, 2010 , Tseng et al., 2002 ). 93 
In addition, use  of amniotic membrane as a substrate for limbal epithelial cell growth has added 94 
the benefits of amnion’s ability to facilitate epithelialization ( Lee and Tseng, 1997 , Tsai and 95 
Tseng, 1988 ), reduce inflammation and scarring (Fernandes et al., 2005, Prabhasawat et al., 96 
2001) , and act as a new and natural basement membrane when the underlying stromal tissue 97 
has been destroyed.  98 
 99 
Combining the expansion of cells ex vivo with cultivation on an amniotic membrane has the 100 
advantage of ensuring a compatible extracellular matrix for the graft, thus increasing its  101 
durability and manipulability  (Zakaria et al., 2010 ). This method is an improvement  over earlier 102 
attempts at the use of engineered corneal surfaces, in which fragile sheets of epithelial cells, 103 
with no substantial underlying stromal support , were transplanted (Nishida et al., 2004 , 104 
Pellegrini et al., 1997) . 105 
 106 
There is no CALEC product available in the U.S., and we have thoroughly reviewed efforts to 107 
produce such a product in other countries . As a result, our first  goal has been to optimize and 108 
standardize the techniques of CALEC preparation for the clinical trial in the U.S. We have 109 
significantly improved upon the quality of the cell therapy product and process of preparation by 110 
using completely defined reagents, preforming additional testing on reagents used (for example 111 
bovine adventitious virus testing), using autologous starting material, removing antibiotics and 112 
murine feeder cells, employing highly reproducible methods for cell isolation,  and expansion and 113 
quality control of the resultant CALEC sheets. These modifications and standardizations were 114 
aimed at enhancing safety and predictability of the patients’ clinical outcomes . Based on the 115 
pre-clinical testing p erformed in the Center for Human Cell Therapy Laboratory the CALEC 116 
constructs are ready for the phase I/II clinical trial. We have received Investigational New Drug 117 
Application (IND #16102) approval from the FDA for our CALEC graft to perform the clinical trial 118 
at the Massachusetts Eye and Ear Infirmary  (MEEI)  for unilateral LSCD. The FDA has advised 119 
us in the setting of aims, inclusion and exclusion criteria, and study design.  120 
 121 
In summary, LSCD is a common cause of serious and prevalent corneal blindness , and there 122 
are significant limitations to the current available treatment options and standards of care .  123 
Taking into consideration prior experience with C ALEC in other countries, we have set a goal to 124 
optimize and standardize the techniques of CALEC preparation for the clinical trial in the U.S. 125 
We have significantly improved upon the quality of the cell therapy product and process of 126 
preparation;  such  modifications and standardizations a re aimed at maximizing safety and 127 
predictability of the participant s’ clinical outcomes . In this application, we will evaluate the safety 128 
and feasibility of our CALEC product as well as its efficacy in treating the LSCD . 129 
 130 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 9 of 51 2. STUDY AIMS  131 
The main aim of the study is t o determine preliminary estimates of the safety  and feasibility  of 132 
cultivated autologous limbal epithelial cell ( CALEC ) transplantation in  the treatment of  unilateral  133 
LSCD.  Secondarily, efficacy of CALEC will be investigated. This secondary objective is  intended 134 
to be exploratory rather than conclusive.  135 
 136 
2.1. PRIMARY OBJECTIVE S 137 
1. Safe ty: To establish the safety of  CALEC  transplantation by determining t he incidence of 138 
primary ocular adverse events  through 18 months of follow -up.  139 
 140 
2. Feasibility:  To establish feasibility of manufacturing CALEC  for corneal  surface 141 
reconstruction.  142 
 143 
2.2. SECONDARY OBJECTIVES 144 
 145 
1. Efficacy:  To investigate whether  CALEC  transplantation is efficacious in treatment  of LSCD 146 
participant s by comparing pre -operative to post-operative clinical parameters  at months 3, 147 
12, and 18.  148 
 149 
 150 
2.3. STUDY CONCLUSIONS  151 
The results of this Phase I/II study will provide guidance on whether to continue to a larger 152 
Phase III study and will also provide preliminary data to help determine sample size for future 153 
trials. Generally, if the study is not halted for feasibility issues, and there are no major safety or 154 
efficacy concerns , a larger study of CALEC could be considered. However, caveats of the study 155 
data and other potential factors outside of the trial will need to be considered and weighed in the 156 
ultimate decision of whether to proceed.   157 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 10 of 51 3. STUDY TIMELINE  158 
The total duration of the study, from funding start date to final analysis and manuscript,  will be 159 
approximately 72 months . This will include study startup, initiation and completion of recruitment 160 
(according to procedures detailed in Section 5), completion of 18 months of follow- up for all 161 
participants  completing a transplant, and study closeout. Details of the study timeline and 162 
milestones can be found in the CALEC Study Policy Document. 163 
 164 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 11 of 51 4. STUDY ORGANIZATION 165 
This is an open label, single- center study to assess safety and feasibility of CALEC 166 
transplantation in participant s with unilateral LSCD. T his study will be performed at the Clinic 167 
Center, Massachusetts Eye and Ear Infirmary  in Boston, MA. The CALEC will be manufactured 168 
in the Connell and O’Reilly Families Cell Manipulation Core Facility (CMCF) at the Dana- Farber 169 
Cancer Institute (DFCI)  in Boston, MA, which will be the Resource Center for this study  (CMCF  170 
DFCI) . The Coordinating Center for this study will be Jaeb Center for Health Research located 171 
in Tampa, FL.  172 
  173 
We will also have two Committees for this study, the Operations Committee and the Data and 174 
Safety Monitoring Committee (DSMC). The Operations Committee, which also functions as both 175 
Executive and Editorial Committees, has the overall responsibility for administering the study 176 
and for making day -to-day operational decisions including the recruitment plan, data capture 177 
and maintenance, protocol compliance, participant retention, and planning of investigator and 178 
other committee meetings. The DSMC will be responsible for reviewing the ethical conduct of 179 
the study and for monitoring the data for evidence of adverse or beneficial treatment effects.  180 
Details of the study organization can be found in the CALEC Study Policy Document.  181 
 182 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 12 of 51 5. POPULATION AND RECRUITMENT  183 
This study includes participant s with unilateral LSCD. All participant s will be recruited at the 184 
Massachusetts Eye and Ear Infirmary  according to Section 5. 3. All study participant s will be 185 
screened and  must fit all criteria described in Sections 5.1 and 5.2 . Should a participant ’s first 186 
biopsy fail, the participant can be rescreened at a later date for possible participation (Section 187 
5.6).  188 
 189 
5.1. PARTICIPANT  INCLUSION CRITERIA   190 
• Male or f emale participant s age 18 to <9 0 years old at time of enrollment  with a minimum life 191 
expectancy of 18 months  192 
• Ability of a participant  or guardian/legal representative to provide written informed consent 193 
and to comply with study assessments for the full duration of the study  194 
• Participant s with unilateral limbal stem cell deficiency (LSCD) as determined by  195 
conjunctivalization of the cornea defined by fibrovascular pannus more than 2 mm from the 196 
limbus into the cornea for ≥6 clock hours  197 
o Ideal candidates will also meet the following additional  criteria , but these will not be 198 
required:  199 
o Lack of limbal palisades of Vogt for ≥9 clock hour s 200 
 201 
5.2. PARTICIPANT  EXCLUSION CRITERIA  202 
5.2.1.  GENERAL EXCLUSION CRITERIA   203 
Confirmed none of the following are present via blood draw at screening visit:  204 
• Uncontrolled diabetes , defined as most recent H bA1c >8.5%  (does not need to be repeated 205 
at screening visit if done within the last 3 months  prior to screening visit ) 206 
• Decreased renal function, defined as  eGFR below 60 mL/min per 1.73 m2 207 
• Aspartate aminotransferase or alanine aminotransferase levels >3x institutional upper limit 208 
of normal  (Institutional upper limit: AST 10 -40 U/L ALT 10- 55 U/L)  209 
• Total bilirubin >2.0 x institutional upper limit of normal (except participant s with known 210 
Gilbert’s syndrome)  (Institutional upper limit: Total Bilirubin 0.0- 1.0 mg/dL)  211 
• Platelet levels <10 0,000 or >450,000 per microliter  212 
• Hemoglobin levels <11 .0 g/dL in men  <10.0 g/dL in women  213 
• Prothrombin time >16 seconds or activated partial thromboplastin time >35 seconds in 214 
participant s not taking warfarin or an international normalized ratio >3 in participant s taking 215 
warfarin  216 
• Human Immunodeficiency Virus ( HIV) infection or Acquired Immune Deficiency Syndrome  217 
(AIDS ) 218 
• Active h epatitis  B or C 219 
 220 
Other criteria:  221 
• Inability to tolerate monitored anesthesia  222 
• Current pregnancy (positive urine test) or lactation, or intent to become pregnant between 223 
enrollment and the first 3 months after transplant  224 
• Participation in another simultaneous medical investigation or trial  225 
• Any medical, psychiatric, debilitating disease/disorder or social condition that in the 226 
judgment of the investigator would interfere with or serve as a contraindication to adherence 227 
to the study protocol or ability to give informed consent 228 
• Signs of current infection, including fever and current treatment with antibiotics  229 
• Presence of  potential  allergy to the CALEC graft or any of the chemical components within 230 
its formulation  231 
 232 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 13 of 51 5.2.2.  EXCLUSION BASED ON  EITHER EYE 233 
• Prior corneal surgery within 30 days  prior to study entry  except placement of amniotic 234 
membrane  235 
• Corneal or ocular surface infection within 30 days prior to study entry or  CALEC type 236 
transplantation  237 
• Ocular surface malignancy  238 
• Severe cicatricial eye disease 239 
 240 
5.2.3.  EXCLUSION BASED ON DONOR EYE 241 
• Conjunctivalization of the cornea defined by fibrovascular pannus more than 2mm from the 242 
limbus into the cornea for ≥3 clock hours  243 
• Lack of limbal palisades of Vogt for ≥3 clock hours  244 
• History of allo -limbal transplantation  245 
• Severe dry eye disease as determined by Schirmer’s test ≤5 mm  246 
 247 
 248 
5.2.4.  EXCLUSION BASED ON RECIPIENT  EYE 249 
• Severe dry eye disease as determined by Schirmer’s test ≤2 mm  250 
 251 
5.3. RECRUITMENT  252 
This study will be conducted in accordance to  the Food and Drug Administration’s (FDA) 253 
regulations . In addition, this study will follow the guidelines set forth in the Health Insurance 254 
Portability and Accountability Act (HIPAA), which are written in 45 CFR 160- 164. 255 
 256 
Potential study participants will be identified by the study investigators and their research team 257 
at the Cornea and Refractive Surgery Service, Massachusetts Eye and Ear Infirmary . A 258 
Research Technician, Study Coordinator, Research Fellow and/  or Investigator will identify  the 259 
patients in their clinic who have unilateral LCSD. Once identified, the study team will evaluate 260 
whether the patient may be able to participate in the study based on their medical record and 261 
the study eligibility criteria. If no definit ive reasons to exclude the patient are found during the 262 
review, the patient will be approached by  their physician (investigator)  to review the study .   263 
 264 
Those patients who volunteer to participate will go over the study details and the consent form 265 
with study staff.  If he or she understands the study, including its risks, and agrees to participate, 266 
they will be asked to  sign a written consen t document . Subsequently , the s creening procedures 267 
will be performed to confirm  the eligibility of the study participant. Once it is determined that the 268 
participant  qualifies to enroll in the study, he or she  will have another visit to provide the 269 
baseline data. After this baseline visit, the participant  will be assigned into a study arm, as 270 
described below in Section 5.5.  The schedule of post -corneal reconstruction visits is standard 271 
for participant s undergoing the se types of procedure s.  272 
 273 
This study does not exclude, or intentionally recruit, participant s based on  gender,  race,  or 274 
ethnicity.  275 
 276 
5.4. INFORMED CONSENT PROCESS  277 
Participant s are required to sign an informed consent  form (ICF) which includes  a Health 278 
Insurance Portability and Accountability Act (HIPAA) authorization form before participating in 279 
the study.  Given that the Investigators  and study staff are responsible for maintaining detailed 280 
knowledge of the study protocol, safety profile,  and previous work with the procedure, these 281 
individuals will discuss the protocol with potential participants and obtain informed consent. The 282 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 14 of 51 study team will review the study procedures, visit schedule, known risks, potential benefits  (if 283 
any), alternative treatments and financial responsibilities with all potential participant s. Each 284 
participant will be informed of their right to withdraw at any time from the study without affecting 285 
their care or relationship with the treating physician and participating institution. A study member 286 
will also explain and discuss with the participant  their confidentiality rights as described in the 287 
HIPAA form.  Participant s will be given the opportunities to ask questions.  An Investigator wi ll 288 
obtain written consent from each participant  prior to any study procedures performed by the 289 
study team .  290 
 291 
A note will be made on the study record that the ICF was signed by the participant. The ICF  will 292 
follow the guidelines set forth by the FDA and Partners Human Research Committee (PHRC) , 293 
which is the Institutional Review Board (IRB) for this study. A copy of the signed consent form 294 
will be given to the participant . 295 
 296 
We do not anticipate a need to obtain on -going consent over the course of the study.  If protocol 297 
amendments result in consent form changes, participants will be re- consented i f the changes 298 
affect data integrity, or affect the participant s’ right s, safety, or well -being.  Legally Authorized 299 
Representatives (LAR) can consent on behalf of participant s who cannot provide their own 300 
consent. Consent by the LAR will be done in accordance with Massachusetts laws and PHRC 301 
requirements.  302 
 303 
5.5. ENROLLMENT  PROCEDURES  304 
There will be two sequential phases of enrollment  – Phase A followed by Phase B.   305 
 306 
Phase A – Staggered  Enrollment  307 
During Phase A, eligible participants completing the screening and baseline visits will be 308 
enrolled in a staggered fashion (described below) to receive CALEC. This will be the procedure 309 
until three participants in Phase A complete  a CALEC transplant (or until halting guidelines  310 
apply, see Section 9.4). During Phase A , the following will apply:  311 
• If a participant enrolls during Phase A but withdraws from the study prior to transplant, the 312 
participant will not count towards the recruitment goal of  three participants required for  313 
Phase A  314 
• If a biopsy is done for a participant in Phase A , and the biopsy is unable to generate a viable 315 
cell sheet for transplant, a second biopsy may be attempted according to the procedure in 316 
Section 5.6.  317 
• Once a given Phase A biopsy attempt has either (1) failed or (2) succeeded and participant 318 
has completed the 2 -week visit, the study team can then proceed to either  of the following: 319 
 Schedule a second biopsy attempt for any prior Phase A participant whose first 320 
biopsy failed (according to Section 5.6)  321 
 Consent and enroll a new participant in Phase A  322 
 323 
• Phase A enrollment ends after three participants in Phase A have completed a CALEC 324 
transplant and the 2- week visit  after transplantation.   After this occurs , Phase B will 325 
begin.    Some additional Phase A participants whose first biopsy failed may complete a 326 
second biopsy after Phase B begins,  and would count towards the Phase A cohort .    327 
 328 
 329 
Phase B – Open Enrollment  330 
During Phase B , eligible participants completing the screening and baseline visit s will be  331 
enrolled to receive CALEC, with no requirements to stagger the enrollments.     332 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 15 of 51  333 
During Phase B, the following will apply:  334 
• If a participant enrolls during Phase B but withdraws from the study prior to transplant , the 335 
participant will not count towards the recruitment goal. 336 
• If a biopsy is done for a participant in Phase B , and the biopsy is unable to generate a viable 337 
cell sheet for transplant, a second biopsy can be attempted according to the procedure in 338 
Section 5.6 . 339 
 340 
 341 
Study enrollment ends as soon as one of the following is met (whichever occurs first):  342 
• A total of 17 CALEC transplants (across Phase A and B) have been completed.  343 
• The last transplant that can reasonably allow 18 months of follow up within the study 344 
timeline as noted in Section 3 has been completed.  345 
 346 
 347 
The Statistical Analysis Plan documents how participants in the study cohort will be analyzed.  348 
 349 
In both P hases, investigators , participant s, and those involved in the study assessments will all 350 
be aware of  (unmasked to)  the study intervention received and appropriate protocol procedures.  351 
 352 
5.6. SECOND BIOPSY   353 
If a participant experiences failure of the biopsy to generate a viable cell sheet, the reasons for 354 
failure will be reviewed. The participant can be rescreened for a second attempt at biopsy and 355 
CALEC construct  if the following are met: (1) the reason for failure is not likely to re -occur for 356 
that participant , (2) a repeat biopsy does not present a significant risk to the participant, and (3) 357 
study enrollment  has not ended.  Failure is considered not likely to re -occur when initial failure is 358 
deemed secondary to culture condition not cell growth (such as evidenced by normal growth of 359 
P0 cells). Second biopsy attempts will be scheduled at least 30 days after the initial biopsy 360 
which is medically appropriate for this type of biopsy procedure. The  screening visit and 361 
baseline visit will be repeated, unless the second biopsy is scheduled to occur within 55 days of 362 
the original screening visit date, in which case only the baseline visit will be repeated. The 363 
second biopsy must occur within 25 days of the second baseline visit. (Note: The second 364 
baseline assessments will not be used as primary baseline values,  but rather will be used to 365 
document any changes, and may be considered for sensitivity analyses .) 366 
 367 
Each participant will be limited to a total of two biopsies. If a second attempt will not be pursued 368 
or the second biopsy also fails to generate a viable cell sheet, the participant may or may not 369 
continue in follow up, as defined by the criteria in Section 5.7.  370 
 371 
5.7. DISCONTINUATION OF STUDY FOLLOW U P AND PARTICIPANTS WHO DO NOT 372 
COMPLETE A TRANSPLANT  373 
A study participant has the right to withdraw from the study at any time.  If a study participant is 374 
considering withdrawal from the study, the principal investigator should personally speak to the 375 
individual about the reasons, and every effort should be made to accommodate him or her. 376 
Participants that decide to withdraw after transplantation will be asked to return to the clinic for 377 
an Early Termination Visit as described in Section 6. 8.12. After discontinuation of study follow 378 
up for any reason, the subject will continue care with their non- study clinician.     379 
 380 
Other considerations for study discontinuation are as follows:  381 
• Prior to biopsy  382 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 16 of 51 o Study participants who are determined to be ineligible for any reason (including 383 
pregnancy) prior to biopsy will not  proceed to biopsy or transplant, and will either  384 
discontinue or postpone and re -screen at a later time.  385 
• After biopsy but prior to transplant  386 
o Study participants who become pregnant will consult with the study doctor and their 387 
Obstetrician/Gynecologist or primary care physician before determining if it is safe for 388 
them to continue with the transplant procedure.  If the decision is made not to 389 
continue with the transplant procedure , the participant  will either  discontinue or 390 
postpone and re -screen at a later time. 391 
o Study participants who are determined to be ineligible for any other reason will 392 
consult with the study doctor before determining if it is safe for them to continue with 393 
the transplant procedure.  If the decision is made not to continue with the transplant 394 
procedure , the participant  will either  discontinue or postpone and re -screen at a later 395 
time. 396 
o Study participants for whom the biopsy fails to generate a viable cell sheet may be 397 
evaluated for a second biopsy according to  Section 5.6 above. If the participant does 398 
not proceed to second biopsy for any reason, or a second biopsy also fails to 399 
generate a viable cell sheet , the participant will discontinue.  400 
o Additionally: Regardless of whether a participant will discontinue,  all participants 401 
who had a biopsy and do  not proceed to transplant will be monitored by the study 402 
team for 30 days to check for any adverse events related to the biopsy procedures .   403 
If the donor eye after biopsy has a complication or adverse event that does not 404 
resolve after 30 days, the study team will also monitor the donor eye until  the 405 
complication resolves.   Those meeting criteria to discontinue, as detailed in the 406 
scenarios above, will discontinue after this time.  407 
• After transplant  408 
o In general, all possible efforts will be employed to ensure participants who completed 409 
transplant are retained through the duration of follow up.  410 
 411 
5.8. TERMINATION OF STUDY  412 
The DSMC can recommend to terminate or temporarily suspend the clinical trial at any time 413 
point. Halting guidelines are described in Section 9.4. Should the study be terminated or 414 
suspended, t he investigators, FDA, and  IRB will be notified. The research staff and the IRB will 415 
determine the best method to notify participants of study termination or suspension to ensure 416 
participant  safety, confidentiality , and data integrity. The investigators will notify all participants 417 
of the termination or suspension and the reasons for such action. 418 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 17 of 51 6. STUDY PROCEDURES, MEASUREMENTS, AND VISIT SCHEDULE  419 
6.1. CALEC MANUFACTURING  420 
Details of CALEC manufacturing have been provided in the Manual of Procedures Section 7.1.  421 
 422 
6.2. PREPARATION AND ADMINISTRATION OF STUDY TREATMENTS  423 
Biopsies and reconstruction CALEC procedures will be performed by the study PI, Dr. Ula 424 
Jurkunas, to minimize  surgeon variability. In extraneous circumstances where Dr. Ula Jurkunas 425 
is not available to perform CALEC biopsy and/or reconstruction procedure, the study co- 426 
investigators Dr. Reza Dana and Dr. Jia Yin will perform the procedures.   427 
 428 
6.2.1.  PREPARATION (CALEC)  429 
6.2.1.1.  LIMBAL BIOPSY  430 
Two days prior to biopsy of the donor eye, all participants will be started on a topical 431 
fluoroquinolone. Some participants may also start on vancomycin in the eye to be biopsied if the 432 
participants are Methicillin- resistant Staphylococcus aureus (MRSA) positive or are considered 433 
to be part of high- risk populations (e.g., health care personnel).  434 
 435 
6.2.1.2.  TRANSPLANTATION 436 
Two days prior to transplantation, the participant  will be started on a topical fluoroquinolone (all 437 
participant s) and potentially vancomycin drops (in participant s that are MRSA positive or in high- 438 
risk populations, e.g., health care personnel) in the recipient eye.  439 
 440 
6.2.2.  ADMINISTRATION  441 
6.2.2.1.  CALEC PROCEDURE –  BIOPSY 442 
1. Participant  will be taken to the preoperative area of the ambulatory surgery center where 443 
standard operating procedures  (SOP)  will be employed in preparing the donor eye for the 444 
surgery.  445 
2. Type of anesthesia will be decided depending upon the age and overall functioning of the 446 
participant . If the procedure is to be performed under general anesthesia (GA), GA consent 447 
will be obtained from the participant  or guardian. Otherwise, monitored intravenous 448 
anesthesia (MIVA) will be performed after the consent.  449 
3. The eye that is to be biopsied will be marked as such and the other eye will be covered.  450 
4. Fluoroquinolone and proparacaine drops will be administered 3 times prior to the procedure.  451 
5. Lidocaine 1% gel will be administered into the eye and the eye will be closed with tape.  452 
6. The participant  will be brought to the operating suite and positioned in a supine position 453 
under the operating microscope in the manner typical for ophthalmic surgery.  454 
7. The operative eye will be cleaned using 5% Betadine solution per standard surgical 455 
protocol. Both the cul -de-sac and the eyelashes will be cleaned.  456 
8. Under sterile conditions, a limbal biopsy of 3 mm-by-3 mm ( 1 clock hour) will be dissected 457 
from superior or inferior portion of the eye, at the discretion of the operating surgeon.  The 458 
actual size of the graft will be measured and captured for data collection.  459 
9. The biopsied material will be placed into the container with HypoThermosol® FRS  for 460 
transfer to the Dana- Farber Cancer Institute.  461 
10. The biopsied site in the conjunctiva will be closed using interrupted sutures  and/or fibrin glue 462 
per the surgeon’s discretion. . 463 
11. Maxitrol or Tobradex ointment or drops will be placed onto the eye , if patient has no known 464 
allergy.  465 
12. Either a patch or shield will be placed over the eye.  466 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 18 of 51 6.2.2.2.  CALEC PROCEDURE –  TRANSPLANTATION  467 
1. The participant  will be taken to the preoperative area of the ambulatory surgery center 468 
where standard operating procedures  (SOP)  will be employed in preparing the recipient eye 469 
for the surgery.  470 
2. Type of anesthesia will be decided depending upon the age and overall functioning of the 471 
participant . If the procedure is to be performed under general anesthesia (GA), GA consent 472 
will be obtained from the participant  or guardian. Otherwise, monitored intravenous 473 
anesthesia (MIVA) will be performed after the consent.  474 
3. In cases of MIVA anesthesia, peribulbar block will be injected in the operated eye.  475 
4. The recipient  eye that is to be operated on (i.e., the eye with LSCD) will be marked as such 476 
and the other eye will be covered.  477 
5. Fluoroquinolone and proparacaine drops will be administered 3 times prior to the procedure.  478 
6. Peribulbar or retrobulbar block with 50:50 mixture of lidocaine and bupivacaine will be 479 
injected into the recipient eye.  480 
7. The participant  will be brought to the operating suite and positioned in a supine position 481 
under the operating microscope in the manner typical for ophthalmic surgery.  482 
8. The operative eye will be cleaned using 5% Betadine solution per standard surgical 483 
protocol. Both the cul -de-sac and the eyelashes will be cleaned.  484 
9. If excessive ocular surface bleeding is detected, topical epinephrine (1:10,000) will be used 485 
to constrict the blood vessels and minimize bleeding prior to or during the procedure. A 486 
conjunctival peritomy may  be performed per investigator discretion. The fibrovascular tissue 487 
will be dissected from the limbus and the cornea. Hemostasis will be achieved by wet -field 488 
cautery.  Mitomycin C may be placed underneath the conjunctiva per the surgeon’s 489 
discretion.  490 
10. The transwell with CALEC graft inside will be removed from the original container and will be 491 
placed on a sterile silicone platform and rinsed with BSS® Sterile Irrigation Solution. A free- 492 
held trephine, size depending on the operated eye,  will be used to punch the graft. The size 493 
of trephine used will be recorded in the operative note.  The transwell with the remnants of 494 
the graft will be lifted off. The trephined CALEC graft on the transwell membrane will be 495 
lifted with the forceps and transferred to the surgical field where the CALEC graft will be 496 
peeled from the transwell membrane and centered onto the ocular surface with epithelium 497 
side up. CALEC will be secured with sutures and/or fibrin glue per the surgeon’s discretion . 498 
The conjunctiva will be closed using sutures and/or fibrin glue per the surgeon’s discretion. 499 
At the end of the procedure, fluorescein will be used to assess epithelial integrity. Lack of 500 
fluorescein uptake in the central cornea will indicate that epithelium of the CALEC graft is 501 
intact.  502 
11. Bandage contact lens will be placed over the graft.  503 
12. Subconjunctival injection of Kefzol and Decadron will be given, if patient has no known 504 
allergy.  505 
13. Maxitrol or Tobradex ointment or drops will be placed onto the eye , if patient has no known 506 
allergy.  507 
14. A patch and/or shield will be placed over the eye.  508 
 509 
6.3. MODIFICATION OF STUDY INTERVENTION FOR A PARTICIPANT  510 
If a participant has an allergy to any of the medications listed in the protocol , that medication will 511 
not be used and/or will be substituted with an appropriate alternative based on the investigators’ 512 
discretion. If participant  has a latex allergy, standard precautions will be employed to avoid latex 513 
products during the peri - and intra -operative periods.  514 
 515 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 19 of 51 6.4. ADDITIONAL SURGERIES  516 
If a participant requires any additional surgeries for visual rehabilitation in the recipient eye, 517 
including cataract surgery or corneal transplantation, the surgeries will be performed at least 3 518 
months after corneal reconstruction with CALEC.  519 
 520 
6.5. MEDICATIONS  AND TREATMENTS   521 
6.5.1.   CONCOMITANT MEDICATION/TREATMENTS  522 
Participants  who enter the study taking anti-glaucoma medication will be able to continue that 523 
medication throughout the duration of the study. If participants  develop increased intraocular 524 
pressure (IOP) during the study , anti-glaucoma medications may be prescribed that include one 525 
or more or in combination form ulations . 526 
 527 
6.5.2.   ACCEPTABLE CONCOMITANT  MEDICATIONS  528 
Participants  will be able to use anti -glaucoma medications. Pa rticipant s will be able to have 529 
increased dose of topical corticosteroids throughout the course of the study if determined to be 530 
necessary by the treating ophthalmologist . Participant s who develop infections will be treated 531 
with appropriate antimicrobial agents  such as antibiotics, anti -viral and/or anti -fungal agents.  532 
Participant s will be allowe d to use ointments that have antibiotic and/or steroid components.  533 
 534 
Whenever possible, non-preserved medications will be prescribed to reduce epithelial toxicity.  535 
 536 
Current medication regimens will not be changed, if possible . 537 
 538 
6.5.3.   PROHIBITED CONCOMITANT MEDICATIONS  539 
• Other investigational treatments  540 
 541 
6.5.4.   STUDY MEDICATION REGIMEN  542 
The pre-study topical ocular medication regimens of all participants will be reviewed at study 543 
enrollment, and may be changed based on investigator’s clinical judgement . All p articipants will 544 
be prescribed a topical fluoroquinolone, a topical steroid 1%, Vancomycin 14 mg/mL  (see 545 
below) , 20%  autologous serum eye drops, and artificial tears  in both eyes as follows. If 546 
participant s have or develop an allergy to the drops, the investigators will prescribe an 547 
appropriate substitute.   The regimen applies to only those participants who complete the biopsy 548 
and/or the transplant, as applicable.  549 
 550 
Screening Visit 551 
If the conjunctival culture taken at screening reveals the presence of MRSA bacteria or the 552 
participant is in a high- risk population for MRSA (i.e. hospital employee), the participant will be 553 
treated with V ancomycin 14 mg/mL, four times per day in both eyes . 554 
 555 
Day 1 Post -Biopsy  Visit 556 
The participant  will s tart a topical fluoroquinolone and  a topical steroid  1% in the donor eye on 557 
Day 1 after biopsy until time of corneal reconstruction (approximately two weeks).   The topical 558 
steroid will be  started at four times per day and adjusted based on clinical judgement.  If 559 
previously using V ancomycin to treat MRSA, the participant  will continue using it four times per 560 
day in both  eyes.  561 
  562 
Day 1 Post -Transplant  Visit (Corneal Reconstruction)  563 
• The participant will start a topical fluoroquinolone and a topical steroid 1% in recipient eye. 564 
S/he will c ontinue regimen until 2-week visit. If previously using Vancomycin to treat MRSA, 565 
the participant  will continue using four times per day in both  eyes. 566 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 20 of 51 • The participant  will start 20% autologous serum eye drops in the recipient eye after corneal 567 
reconstruction and will continue it for at least 1 month.  Dosage will be adjusted based on 568 
clinical judgement.  In addition t he participant  will s tart artificial tears  four times per day in 569 
both eyes  and continue throughout the course of the study. 570 
 571 
1-Week Visit  after Transplant  572 
The participant  will c ontinue all medications as prescribed at Day 1 Post -Graft  visit.  Dosage will 573 
be adjusted based on clinical judgement . 574 
 575 
2-Week Visit after Transplant  576 
• The participant  may start taper of topical fluoroquinolone and topical steroid 1% in the 577 
recipient eye; changes to dosage will be made for individual participants based on clinical 578 
judgement.  The participant will be able to stop the steroid  and fluoroquinolone in the donor 579 
eye, unless inflammation persists in which case usage will continue up to 4 weeks.  580 
• The participant  will c ontinue autologous serum eye drops and artificial tear use four times 581 
per day in both eyes.  Vancomycin will be tapered according t o the same schedule as the 582 
fluoroquinolone and the topical steroid 1%. 583 
 584 
1-Month Visit after Transplant  585 
The participant  will c ontinue all medications as d escribed at  the 2-w eek visit. Around the time of 586 
this visit, participants will be starting their daily  dose of the topical fluoroquinolone and the 587 
topical steroid 1% as described in the taper regimen at the 2-week visit. If the participant was 588 
previously using Vancomy cin, it will be  decreased along the same schedule . The autologous 589 
serum eye drops may be stopped at investigator discretion based on participant  symptoms of 590 
discomfort and epithelial healing. 591 
 592 
3-Month Visit after Transplant  593 
From this point forward, the  participant’s m edication regimen s will no longer follow a  protocol - 594 
dependent  schedule and will be adjusted as medically necessary.  Participant s who have been 595 
MRSA positive will undergo another conjunctival culture and Vancomycin dosing will be 596 
adjusted based on findings. If participant has to continue bandage contact l ens, as determined 597 
by investigator  discretion  based on participant  symptoms of discomfort and epithelial healing, 598 
the fluoroquinolone will be continued for the duration of lens wear.  599 
 600 
6.5.5.  OTHER TREATMENTS  601 
At least one o cular punctal plug will be placed in each  eye as needed for which  the Schirmer’s  602 
Test is below 10 mm and the patient does not have an existing plug or had punctual cautery in 603 
the past. The plug(s) will be placed at the screening visit  and then replaced at subsequent visits 604 
if they fall out. Punctal plugs may also be initiated at any visit per usual clinical practice . A 605 
bandage contact lens will be placed on the treated eye of all subjects up until 30 days post 606 
procedure. The bandage contact lens may continue to be worn past 30 days post procedure if 607 
there is evidence of epithelial defect or if deemed necessary by the treating physician.   608 
 609 
6.6. CLINICAL EVALUATIONS  610 
The following is a summary of how each clinical evaluation will be performed.  Section 6.8 611 
summarizes the study visit schedule and all assessments performed at each visit.  The MOP 612 
provides more details  regarding the order of testing and by whom each assessment is 613 
performed .  614 
 615 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 21 of 51 6.6.1.   SYMPTOM ASSESSMENT  616 
The Ocular Surface Disease Index (OSDI) and Symptom Assessment iN Dry Eye  (SANDE) 617 
questionnaires will be administered by certified study personnel prior to  initiating the ophthalmic 618 
exam.  619 
 620 
6.6.1.1.  OCULAR SURFACE DISEASE INDEX (OSDI)  621 
This disease- specific questionnaire includes three subscales: ocular discomfort (OSDI  622 
symptoms), which includes symptoms such as gritty or painful eyes; functioning (OSDI - 623 
function), which measures limitation in performance of common activities such as reading and 624 
working on a computer; and environmental triggers (OSDI -triggers), which measures the impact 625 
of environmental triggers, such as wind or drafts, on dry eye symptoms (Manual of Procedure 626 
(MOP), Section 21, Vitale et al., 2004).   627 
 628 
6.6.1.2.  SYMPTOM ASSESSMENT IN DRY EYE (SANDE)  629 
The SANDE questionnaire uses a horizontal visual analog technique to quantify each 630 
participant ’s symptomatology with regard to dryness and/or irritation (MOP, Section 22). Each 631 
index will use a 100mm line to individually assess both the average frequency and the average 632 
severity of symptoms of ocular discomfort or dryness experienced by the participant. The 633 
participant  will be asked to put a mark on two given lines to depict the extent of their symptoms 634 
separately in terms of frequency and severit y – the mark will be measured and recorded by the 635 
study team.  636 
 637 
6.6.2.   VISUAL ACUITY  638 
At each visit, participant s’ best corrected visual acuity (BCVA) of both eyes will be assessed by 639 
Snellen visual acuity and recorded (MOP, Section 23) . Manifest refraction  will be performed  if 640 
pinhole improves BCVA more than 1 line.  641 
 642 
6.6.3.  INTRAOCULAR PRESSURE (IOP) EVALUATION 643 
IOP will be evaluated by one or a combination  of the available modalities  noted below 644 
depending on the cooperation of the participant  and ocular appearance on the exam as well as 645 
ability to obtain the reading (MOP, Section 24).  646 
• Tonopen: To measure IOP using tonopen applanation, the Tono -Pen XL (Mentor, Santa 647 
Barbara, CA) will be calibrated daily. Following administration of 0.5% proparacaine 648 
hydrochloride in the cul -de-sac, the pen tip (with disposable cover) will be touched to the 649 
central cornea until a reading is measure. Only measurements with a 5% standard error 650 
will be accepted. If error is greater than 5%, the measurement will be repeated. 651 
• Pneumotonometry: Pneumotonometer (Reichart) measurements will be taken 652 
perpendicularly to the cornea, at the center of the cornea after calibration according to 653 
the manufacturer’s instructions  in the event Tonopen is unable to provide a reading  654 
• Palpation: The IOP of the donor eye will be determined by palpation for one week post 655 
biopsy.  The IOP of the recipient eye will be determined by palpation until the thirteen 656 
week  visit after transplant.  657 
 658 
6.6.4.  SLIT LAMP EXAMINATION 659 
At each visit, participant s will undergo assessment of eyelid, conjunctiva, cornea, and all 660 
intraocular structures of both eyes , by a  certified study investigator  who was not the investigator 661 
performing the biopsy or transplant for that participant . This may include a research associate or 662 
research fellow who does not perform surgeries but functions as a clinical examiner investigator 663 
only.  The number of such investigators will be limited and each will complete sample 664 
assessments on the primary efficacy endpoints (both the corneal epithelial defect surface area 665 
and NEI scale gradings noted below) as part of their study training and certification.   666 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 22 of 51  667 
6.6.4.1.  CORNEAL OPACIFICATION  668 
The cornea will be examined and its opacification will be graded according to the Fantes Scale 669 
(MOP, Section 26) (Fantes et al., 1990).  670 
 671 
6.6.4.2.  CORNEAL FLUORESCEIN STAINING   672 
For the clinical exam with corneal fluorescein staining, a single Akorn FUL -GLO Fluorescein 673 
Sodium strip will be wetted with a drop of sterile saline and applied to the inferior fornix and 674 
examination and photography  (Section 6.6.7.2 below)  will be performed between 2- 5 minutes 675 
after the instillation of fluorescein.    676 
 677 
The entire cornea will be examined using slit lamp evaluation with a yellow barrier filter (#12 678 
Wratten) and cobalt blue illumination (staining is more intense when it is observed with a yellow 679 
filter). Staining with fluorescein will be used to determine presence of corneal epithelial defects. 680 
The extent of corneal fluorescein staining will be evaluated using the National Eye Institute 681 
(NEI) grading scale (MOP, Section 25). Each of five corneal zones  (superior, nasal, central, 682 
inferior, and temporal ) will be graded from 0 (normal) to 3 (severe) and staining score of the 683 
cornea will range  from 0 and 15 points. Epithelial defects (as defined as confluent epithelial 684 
staining of >1 mm2) will be measured at the greatest horizontal and vertical dimensions, and 685 
surface area will be calculated in mm2.   686 
 687 
6.6.5.  SCHIRMER’S TEST  688 
The Schirmer’s test will be performed with anesthesia by placing a narrow filter -paper strip 689 
(5mm × 35mm strip of Whatman #41 filter paper) in the inferior cul -de-sac (MOP, Section 27). 690 
This test is to be conducted in a dimly lit room. The participant  will be instructed to gently close 691 
their eyes until five minutes have elapsed . The strips  will be  removed. Since the tear front will 692 
continue advancing a few millimeters after it has been removed from the eyes, it is important to 693 
mark the tear front with a ball -point pen at precisely five minutes. Aqueous tear production will 694 
be measured by the length in millimeters that the strip wets in 5 minutes.  695 
 696 
6.6.6.  IMPRESSION CYTOLOGY  697 
At 12, 15, and 18 months after transplantation, if there is clinical suspicion of limbal stem cell 698 
deficiency  in the recipient eye , an impression cytology of the ocular surface will be performed to 699 
confirm the diagnosis.  Impression cytology will be performed in the recipient eye  after 700 
application of the topical anesthetic. Nitrocellulose membranes will be firmly pressed onto the 701 
ocular surface (as shown in MOP ) for 5 seconds. Each membrane will cross the limbus so as to 702 
collect cells from the cornea, the limbus, and the conjunctiva. The membranes will then be 703 
removed and fixed in methanol solution immediately. Samples will then be taken to the 704 
pathology laboratory for further staining and analysis.  705 
 706 
6.6.7.  SLIT LAMP PHOTOGRAPHY 707 
Digital corneal photography to measure neovascular area and epithelial defect area will be done 708 
by a certified study photographer  or research associate, using a slit lamp with a digital camera 709 
attachment and a flash -through- the-slit illumination system.  710 
 711 
6.6.7.1.  PHOTOGRAPHY FOR NEOVASCULAR AREA 712 
The entire cornea will be pictured using diffuse illumination and 10x magnification. If lids are 713 
drooping, the photographer will attempt to gently remove them from area of focus with a cotton 714 
swab. Participants with dark iri ses, which may prohibit a clear image, may be dilated with 715 
tropicamide only (without use of an adrenergic agent that may induce vascular ‘blanching’) to 716 
enhance visualization of corneal blood vessels.  Digital photographs will be taken and the 717 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 23 of 51 images will be uploaded into the graphics editing software (ImageJ). The neovascular area will 718 
be calculated as described in MOP. Digital slit lamp corneal pictures will be analyzed using 719 
graphics -editing software (Photoshop) and a mathematical program (Matlab script). After the 720 
total area is delineated, the blood vessels will be isolated using Photoshop. Neovascular area 721 
(in pixels ) is computed using a Matlab script to assist a qualified technician to measure the area 722 
of the vessels themselves.  723 
 724 
6.6.7.2.  PHOTOGRAPHY FOR EPITHELIAL DEFECT AREA  725 
For photography with corneal fluorescein staining, a single Akorn FUL-GLO Fluorescein Sodium 726 
strip will be wetted with a drop of sterile saline and applied to the inferior fornix and examination 727 
(Section 6.6.4.2 above) and photography will be performed between 2- 5 minutes after the 728 
instillation of fluorescein.    729 
 730 
Following staining, the entire cornea will be imaged using cobalt blue filter of the slit lamp. A 731 
magnification of 10x with diffuse illumination will be used. Digital photographs will be taken and 732 
the images will be uploaded into the graphics editing software. The epithelial defect area will be 733 
calculated.  Digital slit lamp corneal pictures will be analyzed using ImageJ . The total area of the  734 
epithelial defect(s) will be measured in pixels. Then, total corneal area will also be measured in 735 
pixels. Then, the ratio of the total corneal area which is covered by epithelial defect(s) will be 736 
calculated in percentage.  737 
 738 
6.6.8.  LID MARGIN AND CONJUNCTIVA CULTURES  739 
Conjunctival cultures will be performed to evaluate the microbiologic colonization at the 740 
screening visit in all participant s and at the 3-  and 12- month visits only if MRSA was detected at 741 
screening. A moistened swab will be used to get specimen from  the lower fornix in each eye, 742 
and will be inoculated above the “R” and “L” on the blood and chocolate plates in the shape of 743 
“C.” The plates will be placed in an incubator set to 35°C with 5% CO 2. All plates will be 744 
observed daily for seven  days for the formation of microbial colonies. The bacteria will be 745 
identified by using standard microbiologic techniques.  746 
 747 
6.6.9.  FUNDUS EXAMINATION 748 
A dilated fundoscopy  (fundus examination)  will be performed to evaluate the fundus for 749 
abnormalities.  If the fundoscopy  cannot be performed, a B-scan ultrasound will be performed 750 
instead to evaluate the fundus for abnormalities.    751 
 752 
6.6.10 ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY  753 
Anterior segment optical coherence tomography (AS -OCT) is a non- contact imaging modality 754 
that provides high- resolution cross -sectional images of ocular structures. The subject will be 755 
positioned in front of the AS -OCT machine (RTVue- 100, OptoVue, Freemont, CA). One scan of 756 
the central cornea and one scan of the limbus in each quadrant (superior, inferior, nasal, and 757 
temporal) will be obtained using an automated scanning algorithm. AS -OCT imaging of both 758 
eyes will be performed at the baseline, 12 and 18 -month post -operative visit. Central epithelial 759 
thickness is calculated by an automatic algorithm. The deepest limbal epithelial thickness in 760 
each quadrant will be measured manually on cross -sectional images. The outcomes are central 761 
corneal epithelial thickness and limbal epithelial thickness in superior, inferior, nasal, and 762 
temporal quadrants. There may be future measurements using these images that are currently 763 
unknown.  AS-OCT will be done by a certified study photographer or research associate.  764 
 765 
6.6.11 IN VIVO CONFOCAL MICROSCOPY  766 
In vivo confocal microscopy (IVCM) is an imaging method that allows visualization of the corneal 767 
structures at the cellular level. A drop of topical anesthetic will be instilled in each eye prior to 768 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 24 of 51 the procedure and a temporary bandage contact lens may be applied prior to imaging for patient 769 
comfort and removed after imaging. One drop of hypromellose 2.5% is applied to the patient’s 770 
eye and one drop of hypromellose 0.3% will be placed on the objective lens of the microscope 771 
according to the manufacturer’s instructions.  IVCM will be performed on each eye with a 772 
Heidleberg retina tomograph (HRTII)/Rostock cornea module (RCM) (Heidelberg Engineering 773 
GmbH, Dossenheim, Germany) with a water -immersion objective lens. One scan of the central 774 
cornea and one scan of each quadrant of the limbus (superior, nasal, temporal, and inferior) will 775 
be obtained. IVCM of both eyes will be performed at the baseline visit, 12 and 18- month post - 776 
operative visits unless patient reports eye pain, discomfort, irritation and cannot tolerate the 777 
procedure, or there is clinical contraindication in the case of corneal epithelial defect, 778 
hemorrhage, or inflammation. Images will be analyzed to determine the presence or absence of 779 
the following cell types: corneal epithelial cells are defined as polygonal cells with bright, well - 780 
defined borders, dark cytoplasm and no visible nuclei; conjunctival cells are defined as cells with 781 
bright nuclei and ill -defined borders.  Limbal palisades of Vogt are defined as hyper -reflective 782 
double contoured linear structures that alternate with islands of epithelial cells. The outcomes 783 
are: presence (or absence) of corneal epithelial cells in the central cornea and limbus, presence 784 
(or absence) of conjunctival epithelial cells in the central cornea and limbus, and the presence 785 
(or absence) of limbal palisades of Vogt. There may be future analysis of the images that are 786 
currently unknown.   IVCM  will be done by a certified study photographer or research associate.  787 
 788 
6.7. LABORATORY EVALUATIONS  789 
Participants will have blood drawn at the Massachusetts Eye and Ear Infirmary Clinical 790 
Laboratory at s creening (see list of tests run at screening). An additional blood draw will be 791 
collected within 7 days before or after  biopsy to test for Hepatitis B , Hepatitis C, and HIV , and 792 
results communicated to CMCF prior to release of the product . 793 
 794 
Additionally, female participants of child- bearing potential will undergo a urine pregnancy test at 795 
screening for study eligibility determination and then again at the visit before CALEC 796 
transplantation.  797 
 798 
Participant s with uncontrolled diabetes, as defined by the most recent H bA1c >8.5% (at the 799 
screening visit or within 3 months prior to screening visit) and with decreased renal function, as 800 
defined by eGFR (estimated glomerular filtration rate) below 60 mL/min per 1.73 m2, will be 801 
excluded from the study. Similarly, we will check lab values for liver enzymes, hemoglobin, 802 
platelets, prothrombin time, partial thromboplastin time, and international normalized ratio. 803 
Aspartate aminotransferase or alanine aminotransferase levels >3x institutional upper limit of 804 
normal  will be considered abnormal.  Total bilirubin >2.0x institutional upper limit of normal 805 
(except participant s with known Gilbert’s syndrome) will be considered abnormal.  Further, 806 
platelet levels <100,000 or >450,000 per microliter, and male hemoglobin of <11.0 g/dL, and 807 
female hemoglobin levels of <10.0 g/dL, will also be consider abnormal. Finally, prothrombin 808 
time >16 seconds or activated partial thromboplastin time >35 seconds in participant s not taking 809 
warfarin, and an international normalized ratio >3 in participant s taking warfarin, will be 810 
considered abnormal.  Participants testing positive for HIV or AIDS or active h epatitis  B or C will 811 
also be excluded.  If any of these lab values are found to be abnormal, the participant s will be 812 
excluded and referred to their primary care physicians fo r further workup and treatment.  813 
 814 
6.8. STUDY SCHEDULE  815 
Below is a summary of the study visit schedule.  The following sections summarize all 816 
assessments performed at each visit.  The MOP provides more details regarding the order of 817 
testing. For a  summary  table of study visit schedule and all assessments performed , see 818 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 25 of 51 Appendi x VII. All visits occur after the participant has been enrolled (after obtaining informed 819 
consent).  820 
 821 
• Screening Visit  822 
• Baseline Visit  –required within 30 days of S creening Visit 823 
• Biopsy - required within 25 days of Baseline Visit  824 
• Post -Biopsy Visit  – required 1 day after biopsy  825 
• Pre-operative Visit  - required 1 to 5 days prior to transplant  826 
• Transplant  – anticipated to occur 10 to 30 days after biopsy    827 
• Day 1, Week 1, Week 2* , and Month 1 Visits  828 
o Same for Phase A and B participants  829 
 Only required for participants who complete a transplant  830 
 Visit schedule is timed from transplant date  831 
• Month 3, 6, 9* , 12, 15 *, and 18 Visits  832 
o Same for Phase A and B participants  833 
 Only required for participants who complete a transplant  834 
 Visit schedule is timed from transplant date  835 
 836 
* The 2 week, 9 month, and 15 month visits will be optional for participants for whom travel is 837 
prohibitive.  For participants who opt out of these visits, the clinical site will work with the 838 
participant’s usual care ophthalmologist on the following:    839 
(1) Advise that the participant follows the protocol’s post -operative medication regimen, 840 
although the regimen will not be enforced by the protocol in these participants.  841 
(2) Request adverse events be reported to the clinical site, under a medical release from 842 
the participant.   843 
 844 
 845 
6.8.1.   STUDY SCREENING   846 
Prospective participants, as defined by the inclusion/exclusion criteria, will be considered for 847 
entry into this study. The study design and treatment regimen will be discussed with each 848 
participant . Written informed consent will be obtained before any study -specific screening 849 
evaluations are performed.  The following evaluations and procedures will be performed for all 850 
participant s during the screening period: 851 
 852 
• Informed consent  process culminating in signed consent document 853 
• Eligibility Assessment  854 
• Record current ocular and systemic medications  855 
• Record medical/surgical history in the past 5 years  856 
• Record demographic data, including date of birth, sex, and race/ethnicity  857 
• Review of systems  858 
• Blood draw for  testing for confirmation of eligibility  criteria, including : 859 
o Hepatitis B  860 
o Hepatitis C  861 
o HIV, AIDS  862 
o CBC (including platelet and hemoglobin levels)  863 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 26 of 51 o eGFR  864 
o HbA1c, if needed (does not need to be repeated at screening visit if done 865 
within the last 3 months prior to screening visit)  866 
o Aspartate aminotransferase and alanine aminotransferase  levels  867 
o Bilirubin  levels  868 
o Prothrombin and thromboplastin time   869 
• Urine pregnancy test for women of childbearing potential  870 
• Slit lamp examination (both eyes) , including 871 
o Corneal opacification (as defined by Fantes Scale) (both eyes)  872 
o Staining with fluorescein (extent of staining and epithelial defect area) 873 
(both eyes)   874 
• Visual Acuity BCVA (both eyes)  875 
• Conjunctival swab and culture (both eyes)  876 
• Intraocular pressure (both eyes)  877 
• Fundus examination or B-scan ultrasound (both eyes)  878 
• Slit lamp photographs (both eyes) by certified technician, including 879 
o Photography for neovascular area  880 
o Photography (with fluorescein) for epithelial defect  881 
• Schirmer ’s test with anesthesia (both eyes)  882 
• Referral to primary care physician to confirm general health prior to surgery, as needed 883 
according to MEEI hospital  SOPs  884 
• Punctal plugs, if needed  (Section 6.5.5 ) (both eyes)  885 
 886 
In addition, blood draw will be performed for autologous serum eye drops prior to transplantation 887 
per CMCF guidelines . 888 
 889 
6.8.2.  BASELINE  (WITHIN 30 DAYS OF SCREENING VISIT ) 890 
A baseline visit will be conducted after a participant  is considered eligible to participate as 891 
determined by the screening visit.  Baseline visit procedures must occur within 30 days after the 892 
screening visit  893 
  894 
Baseline procedures may be conducted over m ultiple visits after screening . 895 
 896 
The following procedures will be conducted for  the baseline visit:  897 
 898 
• Review of pre -operative health screening results to confirm general health prior to surgery 899 
according to MEEI  hospital  SOPs   900 
• Slit lamp examination (both eyes) , including 901 
o Corneal opacification (as defined by Fantes Scale) (both eyes)  902 
o Staining with fluorescein (extent of staining and epithelial defect area)  (both eyes)  903 
• Visual acuity  BCVA (both eyes)  904 
• Intraocular  pressure  (both eyes)  905 
• Slit lamp  photographs  (both eyes)  by certified technician, including 906 
o Photography for neovascular area  907 
o Photography (with fluorescein) for epithelial defect  908 
• Anterior Segment Optical Coherence Tomography  909 
• In Vivo Confocal Microscopy  910 
• Punctal plugs,  if needed  (Section 6.5.5 ) (recipient eye only)  911 
• Assessment  of changes in medical conditions since screening   912 
• Symptom assessment  913 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 27 of 51  914 
 915 
In addition, within seven  days before or after  limbal biopsy, blood draw will be performed for 916 
donor serology testing  in CALEC participants only . 917 
 918 
6.8.3.  LIMBAL BIOPSY (WITHIN 25 DAYS OF BASELINE VISIT ) 919 
Following the baseline visit , a biopsy of the donor eye will be taken as an out patient  procedure 920 
for all participants receiving the CALEC . The biopsy must occur within 25  days after the 921 
baseline visit. Refer to section 6. 2. 922 
 923 
6.8.4.  TRANSPORTATION OF TISSUE TO CMCF  & PREPARATION OF CALEC  924 
If participant s are enrolled in the CALEC arm, t he tissue taken from the donor eye during the 925 
biopsy will be taken to Connell and O’Reilly Families Cell Manipulation Core Facility (CMCF) at 926 
the Dana- Farber Cancer Institute (DFCI)  per operating procedures  (MOP, Section 7).   927 
 928 
6.8.5.  POST -BIOPSY ASSESSMENT OF DONOR E YE (1-2 DAY S AFTER CALEC BIOPSY)  929 
• Slit lamp examination (donor eye) including 930 
o Staining with fluorescein (extent of staining and epithelial defect area)  931 
• Visual acuity   (BCVA) (donor eye)  932 
• Intraocular pressure (donor eye)  933 
• Adverse event assessment    934 
• Slit lamp  photos  (donor eye)  by certified technician, including:  935 
o Photography (with fluorescein) for epithelial defect  936 
• Punctal plug placement, if needed (Section 6.5.5 ) 937 
 938 
6.8.6.  TRANSPORTATION OF CALEC FROM CMCF TO MEEI  939 
The CALEC  is anticipated to be released 10 to 30 days after biopsy, upon which it  will be 940 
transported from CMCF to MEEI (MOP, Sections 7.1.3 and 7.1.4).  941 
 942 
6.8.7.  PREOPERATIVE ASSESSMENT OF RECIPIENT EYE ( 1 TO 5 DAYS PRIOR TO 943 
TRANSPLANT )  944 
A preoperative assessment will be evaluated prior to reconstruction to confirm fitness for 945 
reconstruction of the recipient eye. All participants will receive this preoperative assessment  1 to 946 
5 days  prior to the day of corneal reconstruction (transplant).  947 
 948 
The following procedures will be performed at these visits : 949 
• Urine pregnancy test for women of childbearing potential  950 
• Slit lamp examination (recipient eye) including  951 
o Corneal opacification (as defined by Fantes Scale)  952 
o Staining with fluorescein (extent of staining and epithelial defect area)  953 
• Visual acuity BCVA (recipient eye)  954 
• Intraocular pressure (recipient eye)  955 
• Adverse event assessment  956 
• Punctal plugs, if needed  (Section 6.5.5 ) (both eyes)  957 
 958 
Participants will be asked to report any pregnancies that occur within three days prior to 959 
surgery.  960 
 961 
6.8.8.  CORNEAL RECONSTRUCTION WITH CALEC  (DAY 0)  962 
Participants will undergo corneal reconstruction within 24 hours of release of CALEC.   963 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 28 of 51  964 
A detailed description of the procedures can be found in Section 6.2.2. All participants will be 965 
discharged the day of surgery, unless unforeseen complications prohibit discharge. If a 966 
participant is admitted for observation, the Day 1 post -operative visit will occur while the 967 
participant is in the hospital. All other visits will follow as originally scheduled.  968 
 969 
6.8.9.  FOLLOW -UP PERIOD  970 
Each participant  will be followed for a period of 18  months from the time of the transplantation.  971 
 972 
Participants will be asked to report any pregnancies that occur within seven days after 973 
transplant . 974 
 975 
6.8.10.  POST -TRANSPLANT  (DAY 1 ) 976 
• Slit lamp examination (both eyes)  including  977 
o Corneal opacification (as defined by Fantes Scale)  (both eyes)  978 
o Staining with fluorescein (extent of staining and epithelial defect area) ( donor eye  979 
required;  recipient eye at discretion of investigator  ) 980 
• Visual acuity   (BCVA) (both eyes)  981 
• Intraocular pressure (both eyes)  982 
• Slit lamp  photographs  (both eyes ) by certified technician, including 983 
o Photography for neovascular area  984 
o Photography (with fluorescein) for epithelial defect  (donor eye required ; recipient 985 
eye at discretion of  clinician ) 986 
• Punctal plugs, if needed  (Section 6.5.5 ) (both eyes)  987 
• Application of bandage contact lens, if needed  (Section 6.5.5 ) 988 
• Adverse event assessment  989 
 990 
6.8.11.  POST -OP FOLLOW -UP: WEEKS 1, 2, MONTH 1 ( 4 WEEKS ± 3 DAYS)  AND 991 
MONTHS 3, 6, 9, 12 ( 13, 26, 39, 52 WEEKS ± 1 WEEK) , AND MONTHS 15, AND 18 ( 65 AND 992 
78 WEEKS ±2 WEEKS)  993 
• Symptom assessment  (every visit except week 1, week 2, month 1)  994 
• Slit lamp examination (both eyes)  including  995 
o Corneal opacification (as defined by Fantes Scale) (both eyes)  996 
o Staining with fluorescein (extent of staining and epithelial defect area) ( donor  eye 997 
required;  recipient eye at discretion of investigator  at week 1 and 2, and required at 998 
month 1 and thereafter .)  999 
• Visual acuity  BCVA (both eyes)  1000 
• Intraocular pressure (both eyes)  1001 
• Slit lamp photographs  (both eyes ) by certified technician, including 1002 
o Photography for neovascular area  1003 
o Photography (with fluorescein) for epithelial defect  (donor eye required ; recipient eye 1004 
at discretion of investigator at week 1 and 2, and required at month 1 and thereafter)  1005 
• Anterior Segment Optical Coherence Tomography  (months 12 and 18)  1006 
• In Vivo Confocal Microscopy (months 12 and 18)  1007 
• Punctal plugs, if needed  (Section 6.5.5 ) 1008 
• Application of bandage contact lens, if needed  (Section 6.5.5 ) 1009 
• Conjunctival swab and culture ( months 3 and 12,  only if MRSA was detected at screening  1010 
visit) 1011 
• Impression cytology ( in the recipient eye will be done as needed to confirm clinically 1012 
suspect ed LSCD months 12, 15, and 18 )  1013 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 29 of 51 • Adverse event assessment  1014 
 1015 
6.8.12.  EARLY TERMINATION VISIT  1016 
Participant s who withdraw from the study or are unable to complete all of the study visits will be 1017 
asked to complete an early termination visit prior to discontinuing their participation. The early 1018 
termination visit will include the  following : 1019 
 1020 
• Symptom Assessment  1021 
• Visual acuity  (BCVA)  (both eyes)  1022 
• Intraocular pressure (both eyes)  1023 
• Slit lamp examination (both eyes)  including  1024 
o Corneal opacification (as defined by Fantes Scale) (both eyes)  1025 
o Staining with fluorescein (extent of staining and epithelial defect area) (both eyes)  1026 
• Slit lamp photographs  (both eyes)  by certified technician, including 1027 
o Photography for neovascular area  1028 
o Photography (with fluorescein) for epithelial defect  1029 
• Punctal plugs, if needed ( Section 6.5.5 ) 1030 
• Bandage contact lens, if needed (Section 6.5.5 ) 1031 
• Adverse event assessment  1032 
 1033 
6.8.13.  UNSCHEDULED VISIT  1034 
Should a study participant  need to be seen for medical reasons at a time point outside of the 1035 
study protocol, the visit will follow the Week 1 schedule. Assessments may include, but are not 1036 
limited to:  1037 
• Visual acuity BCVA (both eyes)  1038 
• Intraocular pressure (both eyes)  1039 
• Slit lamp examination (both eyes)  including  1040 
o Corneal opacification (as defined by Fantes Scale) (both eyes)  1041 
o Staining with fluorescein (extent of staining and epithelial defect area) ( each eye  at 1042 
discretion of investigator ) 1043 
• Punctal plugs, if needed  (Section 6.5.5 ) 1044 
• Bandage contact lens, if needed ( Section 6.5.5 ) 1045 
• Adverse event assessment  1046 
 1047 
  1048 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 30 of 51 7. OUTCOME MEASURES 1049 
The following is a summary of the definition of the outcome measures. The Statistical Analysis 1050 
Plan details the analysis approach for all outcomes.   1051 
 1052 
7.1. PRIMARY OUTCOME MEASURES 1053 
7.1.1.  SAFETY MEASURES 1054 
The occurrence of the following adverse events at any time during the 18 months of follow -up in 1055 
the recipient eye will serve as the primary safety events of interest :   1056 
 1057 
1. Ocular infection  (defined as endophthalmitis or  microbial  keratitis  [bacterial, fungal, 1058 
parasitic] ) 1059 
2. Corneal perforation 1060 
3. Graft detachment ≥50%  1061 
 1062 
In addition to the primary safety events, all adverse events (systemic and ocular in donor and 1063 
recipient eyes ) will be captured. The severity of each adverse event and the relationship of the 1064 
event to the cell therapy procedure will be assessed by an independent Medical Monitor (s) 1065 
(MM) . The independent Medical Monitor’s (see Section 9. 3) coding of the adverse event and 1066 
designation of severity and relatedness to treatment will serve as final to use for adverse event 1067 
reporting and safety outcome analysis.  1068 
 1069 
7.1.2.  FEASIBILITY MEASURES 1070 
Manufacturing feasibility will be evaluated for each biopsy attempt.  At least one CALEC 1071 
construct will be attempted to be manufactured from each biopsy, as detailed in the MO P. Each 1072 
attempted construct will undergo Quality Control (QC) testing to determine  product conformity to 1073 
CMCF release criteria per MOP , which includes assessments of cell growth, cell viability , and 1074 
culture contamination.   If all of these QC  release criteria are met  for at least one CALEC 1075 
construct , the biopsy attempt is considered a feasibility success .  1076 
 1077 
In the event that a construct met all QC release criteria, but surgery  was not performed for a 1078 
reason unrelated to the development of construct for transplant, the case would still be 1079 
considered a feasibility success for the biopsy attempt.  1080 
 1081 
Up to two biopsy attempts of a single participant  may be performed according to Section 5 . 1082 
Feasibility analysis will explore both  the number of biopsies per participant and the number of 1083 
construct attempts per biopsy, and whether those construct attempts met QC release criteria. 1084 
Each of the i ndividual QC testing and acceptance criteria will be documented to further  describe 1085 
constructs that did not meet the criteria for release.   1086 
 1087 
7.2. SECONDARY OUTCOME MEASURES  1088 
Efficacy Measures:  The primary efficacy outcome will be a binary  “Complete  Succes s” of the 1089 
graft,  as defined below.    Secondarily, “Partial Success”  will also be considered according to a 3 1090 
category outcome defined below .   1091 
1. “Complete Success” will be defined as improvement  in corneal surface integrity   1092 
2. “Partial  Success” will be defined as  1093 
a. No improvement in corneal surface integrity and  1094 
b. Improvement in either  1095 
i. Extent of corneal vascularization or  1096 
ii. Participant  symptomatology  1097 
3. Otherwise, not a success  1098 
 1099 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 31 of 51 Improvement in each area is defined as follows, where changes are measured relative to 1100 
the Baseline visit :  1101 
• Corneal surface integrity    1102 
o If epithelial defect surface area (based on clinical assessment) at the Baseline 1103 
visit is > 0  mm2, then improvement  will be defined as:  1104 
 Decrease in epithelial defect surface area (based on clinical assessment 1105 
by an independent investigator, not the treating surgeon, as described in 1106 
the MOP) by ≥75%  1107 
o If epithelial defect surface area (based on clinical assessment) at the Baseline 1108 
visit is = 0  mm2, then improvement  will be defined as:  1109 
 Epithelial defect surface area of 0  mm2 and  1110 
 Decrease in corneal surface staining (based on clinical assessment by an 1111 
independent investigator, not the treating surgeon, using NEI grading 1112 
scale) by ≥50%   1113 
• Extent of corneal vascularization  1114 
o Decrease in neovascular area  (based on digital slit lamp photograp hs, using 1115 
mathematical software to calculate as described in the MOP)  by ≥25%  1116 
• Participant  symptomatology  1117 
o Decrease in Ocular Surface Disease Index (OSDI) score by ≥25% or 1118 
o Decrease in Symptom Assessment i n Dry Eye (SANDE) score by ≥25%  1119 
 1120 
The primary efficacy  time points will be at 3 months (to assess early success), as well as 12 and 1121 
18 months (to assess late success). Effic acy outcomes at all interim post -3 month time points 1122 
will also be evaluated secondarily. The pattern of efficacy outcomes for an eye at these and all 1123 
interim time points 3 months and later will be evaluated secondarily to assess the degree of 1124 
stability of each level of success over time . 1125 
 1126 
7.3. OTHER OUTCOME MEASURES  1127 
In addition to the primary and secondary outcome measures defined above, distribution of data 1128 
and summary statistics will be evaluated on the following at each time point where relevant data 1129 
are collected : IOP, impression cytology, corneal opacification, visual acuity , AS- OCT outcomes 1130 
(central corneal epithelial thickness and limbal epithelial thickness in superior, inferior, nasal, 1131 
and temporal quadrants), and IVCM outcomes (presence of corneal epithelial cells, presence of 1132 
conjunctival epithelial cells, and the presence of limbal palisades of Vogt .) All reported adverse 1133 
events will also be tabulated.  1134 
 1135 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 32 of 51 8. MONITORING STUDY PROGRESS  1136 
Study progress will be monitored weekly or bi -weekly on Operations Committee calls. 1137 
Recruitment reports will be available on the study website to monitor recruitment progress and 1138 
ultimately follow up completion relative to the projected timeline. Operations Committee calls will 1139 
also serve to keep all units of the Coordinating Center, Clinical Center, and PIs informed and 1140 
engaged with the day -to-day progress of whether study goals are being met, including 1141 
successful study oversight (including safety monitoring  and protocol adherence monitoring of 1142 
the monitoring plan)  and eventually plans for closeout, manuscripts , and dissemination of study 1143 
results. The Operations Committee will also monitor study progress with regards to timeliness 1144 
and achievement of study goals.  1145 
 1146 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 33 of 51 9. ASSESSMENT OF SAFETY  1147 
 1148 
9.1. METHODS AND TIMING FOR ASSESSING , RECORDING , AND REPORTING OF  1149 
SAFETY PARAMETERS  1150 
All adverse events  will be assessed by investigators and recorded at each visit following the 1151 
baseline visit . 1152 
 1153 
Details of recording and reporting adverse events have been provided i n MOP . 1154 
 1155 
Details of monitoring and reporting adverse events  can be found in the Monitoring Plan.  1156 
 1157 
9.2. SAFETY OVERSIGHT  1158 
Independent Medical Monitors (MMs) will be appointed to this study and will review any reported 1159 
adverse events on a periodic basis  to independently evaluate all adverse events. The MMs will 1160 
be designated from the EMMES Corporation, Rockville, MD and will be unaffiliated with the 1161 
CALEC study in any other way. The MMs are responsible for periodic  review of all adverse 1162 
events and within 24 hours  of notification  for cases that require any expedited reporting (for 1163 
which an auto -email notification alert at the time of data entry will be generated). Details of the 1164 
adverse event review by the MM can be found in the Monitoring Plan. The MM coding of the 1165 
adverse event and designation of severity and relatedness to treatment will serve as final to use 1166 
for adverse event reporting and safety outcome analysis.  1167 
 1168 
The DSMC will be responsible for reviewing the ethical conduct of the study and for monitoring 1169 
the data for evidence of adverse or beneficial treatment effects.   Adverse events will be reported 1170 
to the DSMC according to the following:  1171 
• All adverse events will be reviewed with the  full DSMC on a periodic basis.  1172 
• A subset of  adverse events will be reported expeditiously  to designated DSMC members , as 1173 
defined by the DSMC in the DSMC Charter .     1174 
• During Phase A, designated DSMC members  will also be provided with a full report of all 1175 
adverse events for each Phase A participant who completed CALEC transplant, upon 1176 
completion of their 2 week visit, to review prior to the consenting and enrolling of the next  1177 
study  participant  (or prior to proceeding to a second biopsy for a Phase A participant) . 1178 
• Also, if criteria for consid ering temporary or permanen t suspension of the trial  are met 1179 
(Section 9. 3), the DSMC will be notified expeditiously.  1180 
 1181 
Details of safety oversight by the DSMC can be found in the Monitoring Plan and the DSMC 1182 
Charter.   1183 
 1184 
9.3. STUDY HALTING GUIDELINES  1185 
The DSMC may recommend at any time whether the study should continue per protocol, be 1186 
further investigated, be discontinued, or be modified and then proceed. The FDA may also 1187 
suspend additional enrollment and study interventions/administration of study product for the 1188 
entire study, if applicable.  1189 
 1190 
There will be no formal  halting guidelines for safety, as the DSMC will receive full safety reports 1191 
on Phase A participants  as noted  in Section 9.2 above, and will also expeditiously receive some  1192 
events  as noted in Section 9.2 above throughout the duration of the study.   1193 
 1194 
 1195 
Halting guidelines for feasibility are as follows:  1196 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 34 of 51 • A temporary suspension of enrollment will occur if four of the first eight CALEC biopsies, 1197 
across Phases A and B, result in failure.  1198 
o This could include two biopsies originating from one participant, (i.e., each biopsy 1199 
would count separately)  1200 
o Multiple construct attempts based on the same biopsy would be considered inclusive 1201 
of a single biopsy  1202 
• If this criterion  is met, the DSMC will be notified expeditiously and enrollment  activities  will 1203 
be temporarily suspended until further direction from the DSMC.  Starting from the time the 1204 
criteria are identified as met, until the time the DSMC provides further direction, the 1205 
temporary suspension of enrollment activities will be defined as follows.   1206 
o No participants will be consented  1207 
o Participants  who have consented and are in some stage of completing screening or 1208 
baseline visits  will be on hold (labs values that have already been processed may be 1209 
collected and entered into the CRF)  1210 
o Participants who have not completed a biopsy will be on hold  1211 
o Participants who had already completed transplant and thus in follow up will not  be 1212 
on hold 1213 
 1214 
  1215 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 35 of 51 10. MONITORING PROTOCOL ADHERENCE  1216 
Details for monitoring clinical site for protocol adherence can be found in the Monitoring Plan.  1217 
The Clinical Center will oversee personnel training and certification, IRB approval and reporting, 1218 
participant recruitment and retention. The day -to-day local clinical procedures monitoring will be 1219 
performed by the Clinical Research Supervisor with the support of study website reports 1220 
provided by the Coordinating Center. The monitoring will be conducted to ensure human 1221 
participant  protection, study procedures, laboratory, study intervention administration, and data 1222 
collection processes are of high quality and meet ICH E6 and MEEI regulatory guidelines. The 1223 
Coordinating Center will be responsible for conducting the monitoring visits and ensuring that 1224 
monitoring findings are reported to the PIs, who will then report to the IRB as necessary and are 1225 
promptly addressed by the Study Coordinator.  1226 
 1227 
The Coordinating Center will provide support via reports and queries for the Clinical Center 1228 
oversight noted above, including reports for monitoring participant status and visit status 1229 
(upcoming, pending, past due, missed). In addition, the Coordinating Center will develop and 1230 
oversee a system for identifying via database queries, documenting, and reporting protocol and 1231 
procedural deviations to the Clinical Center, PIs, IRB and DSMC. The Coordinating Center will 1232 
be responsible for conducting on- site monitoring visits with  support of  the Clinical Center Clinical 1233 
Research Supervisor. Additional accountability and oversight will be reinforced by Operations 1234 
Committee monitoring of the activities noted above. This will include reports and review of 1235 
recruitment, retention, and protocol deviations on at least a monthly basis.   1236 
 1237 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 36 of 51 11. QUALITY CONTROL OF DATA 1238 
Quality control details can be found in the Monitoring Plan. A major function of the Coordinating 1239 
Center is to assure that high quality data are collected so that valid analyses can be conducted. 1240 
The Coordinating Center will collaborate with the Clinical Center and PIs to provide the structure 1241 
and support to enforce and confirm high quality data are being received. Data are verified on 1242 
multiple levels across all stages of the study. In brief, this will include development of the 1243 
following systems, as well as the monitoring and resolution of data issues identified via these 1244 
systems:  1245 
1. Source Data / Data Entry Validations: Study data will be collected by completion of an 1246 
electronic Case Report Form (eCRF) , and via paper versions of the case report forms  (CRF)  1247 
as needed. eCRFs  and CRFs  serve as the primary source document for data collection on 1248 
study participant s and data can be readily entered on the study website directly into the 1249 
Coordinating Center’s database. Data entry validations include logic and contingency 1250 
checks at the time of data entry on the website. Validations will also apply to edits made to 1251 
the eCRFs. Edits are tracked via an audit table in the database.  1252 
2. Protocol Review: Study data will undergo near real time monitoring in which an automated 1253 
regular (weekly or monthly) ‘protocol review’ program runs checks including cross form 1254 
contingencies, write in fields, and data abnormalities, for review and feedback to the Clinical 1255 
Center.  1256 
3. Data Cleaning: Data cleaning programs will be run periodically on frozen datasets for DSMC 1257 
monitoring reports and to be conducted at the end when the database is locked.  1258 
4. Quality Control Reports: Reports will be generated for use by Coordinating Center, Clinical 1259 
Center, and for review by oversight committees.  1260 
 1261 
Site Monitoring and Protocol Adherence: Quality control of data also includes monitoring of 1262 
protocol adherence as described in the prior section.  1263 
 1264 
  1265 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 37 of 51 12. CONTINUED FOLLOW UP FOR CLAU PARTICIPANT ENROLLED PRIOR TO 1266 
PROTOCOL AMENDMENT DISCONTINUING CLAU ARM OBJECTIVE    1267 
Prior to v5.0 of the CALEC Protocol, a secondary objective of the study was to compare CALEC 1268 
efficacy and safety measures with the standard treatment alternative, CLAU.  Phase B of the 1269 
study was designed to randomize participants to receive either CALEC or the standard 1270 
treatment alternative, CLAU. Due to recruitment challenges, v5.0 amended the P rotocol to  1271 
discontinue the CLAU comparison objective and enroll participants for CALEC treatment only.  1272 
At the time of the protocol amendment, one participant had been randomized to the CLAU 1273 
group and completed follow up through at least the 9 month visit.  The prior versions of the 1274 
protocol describe the biopsy, transplant, and medication regimen procedures that applied to this 1275 
participant.  The participant will continue to be followed with the remainder of the follow up visits 1276 
and testing procedures that were required for the CLAU group.        1277 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 38 of 51 13. LITERATURE REFERENCES  1278 
Baradaran- Rafii, A., Ebrahimi, M., Kanavi, M. R., Taghi -Abadi, E., Aghdami, N., Eslani, M., 1279 
Bakhtiari, P., Einollahi, B., Baharvand, H. & Javadi, M. A. (2010). Midterm outcomes of 1280 
autologous cultivated limbal stem cell transplantation with or without penetrating 1281 
keratoplasty. Cornea,  29, 502-9. 1282 
Basu, S., Ali, H. & Sangwan, V. S. (2012). Clinical Outcomes of Repeat Autologous Cultivated 1283 
Limbal Epithelial Transplantation for Ocular Surface Burns. Am J Ophthalmol . 1284 
Clinch, T. E., Goins, K. M. & Cobo, L. M. (1992). Treatment of contact lens -related ocular 1285 
surface disorders with autologous conjunctival transplantation. Ophthalmology,  99, 634- 1286 
8. 1287 
Copeland, R. A., Jr. & Char, D. H. (1990). Limbal autograft reconstruction after conjunctival 1288 
squamous cell carcinoma. Am J Ophthalmol,  110, 412-5. 1289 
Dietrich -Ntoukas, T., Hofmann- Rummelt, C., Kruse, F. E. & Schlotzer -Schrehardt, U. (2012). 1290 
Comparative Analysis of the Basement Membrane Composition of the Human Limbus 1291 
Epithelium and Amniotic Membrane Epithelium. Cornea.  1292 
Dua, H. S. & Azuara -Blanco, A. (1999). Allo- limbal transplantation in patients with limbal stem 1293 
cell deficiency. Br J Ophthalmol,  83, 414-9. 1294 
Dua, H. S. & Forrester, J. V. (1990). The corneoscleral limbus in human corneal epithelial 1295 
wound healing. Am J Ophthalmol,  110, 646-56. 1296 
Dua, H. S., Miri, A. & Said, D. G. (2010). Contemporary limbal stem cell transplantation - a 1297 
review. Clin Experiment Ophthalmol,  38, 104-17. 1298 
Fernandes, M., Sridhar, M. S., Sangwan, V. S. & Rao, G. N. (2005). Amniotic membrane 1299 
transplantation for ocular surface reconstruction. Cornea,  24, 643-53. 1300 
Fogla, R. & Padmanabhan, P. (2005). Deep anterior lamellar keratoplasty combined with 1301 
autologous limbal stem cell transplantation in unilateral severe chemical injury. Cornea,  1302 
24, 421-5. 1303 
Grueterich, M., Espana, E. M. & Tseng, S. C. (2003). Ex vivo expansion of limbal epithelial stem 1304 
cells: amniotic membrane serving as a stem cell niche. Surv Ophthalmol,  48, 631-46. 1305 
Haamann, P., Jensen, O. M. & Schmidt, P. (1998). Limbal autograft transplantation. Acta 1306 
Ophthalmol Scand,  76, 117-8. 1307 
Holland, E. J. & Schwartz, G. S. (1996). The evolution of epithelial transplantation for severe 1308 
ocular surface disease and a proposed classification system. Cornea,  15, 549-56. 1309 
Holland, E. J. & Schwartz, G. S. (1999). Epithelial stem -cell transplantation for severe ocular - 1310 
surface disease. The New England journal of medicine,  340, 1752- 3. 1311 
Holland, E. J. & Schwartz, G. S. (2000). Changing concepts in the management of severe 1312 
ocular surface disease over twenty -five years. Cornea,  19, 688-98. 1313 
Jenkins, C., Tuft, S., Liu, C. & Buckley, R. (1993). Limbal transplantation in the management of 1314 
chronic contact -lens-associated epitheliopathy. Eye (Lond),  7 ( Pt 5) , 629-33. 1315 
Kenyon, K. R. & Tseng, S. C. (1989). Limbal autograft transplantation for ocular surface 1316 
disorders. Ophthalmology,  96, 709-22; discussion 722- 3. 1317 
Koizumi, N., Inatomi, T., Quantock, A. J., Fullwood, N. J., Dota, A. & Kinoshita, S. (2000). 1318 
Amniotic membrane as a substrate for cultivating limbal corneal epithelial cells for 1319 
autologous transplantation in rabbits. Cornea,  19, 65-71. 1320 
Koizumi, N., Inatomi, T., Suzuki, T., Sotozono, C. & Kinoshita, S. (2001). Cultivated corneal 1321 
epithelial stem cell transplantation in ocular surface disorders. Ophthalmology,  108, 1322 
1569- 74. 1323 
Kolli, S., Ahmad, S., Lako, M. & Figueiredo, F. (2010). Successful clinical implementation of 1324 
corneal epithelial stem cell therapy for treatment of unilateral limbal stem cell deficiency. 1325 
Stem cells,  28, 597-610. 1326 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 39 of 51 Kruse, F. E., Chen, J. J., Tsai, R. J. & Tseng, S. C. (1990). Conjunctival transdifferentiation is 1327 
due to the incomplete removal of limbal basal epithelium. Invest Ophthalmol Vis Sci,  31, 1328 
1903- 13. 1329 
Lee, S. H. & Tseng, S. C. (1997). Amniotic membrane transplantation for persistent epithelial 1330 
defects with ulceration. Am J Ophthalmol,  123, 303-12. 1331 
Morgan, S. & Murray, A. (1996). Limbal autotransplantation in the acute and chronic phases of 1332 
severe chemical injuries. Eye (Lond),  10 ( Pt 3) , 349-54. 1333 
Nakamura, T., Inatomi, T., Sotozono, C., Ang, L. P., Koizumi, N., Yokoi, N. & Kinoshita, S. 1334 
(2006). Transplantation of autologous serum -derived cultivated corneal epithelial 1335 
equivalents for the treatment of severe ocular surface disease. Ophthalmology,  113, 1336 
1765- 72. 1337 
Nakamura, T., Koizumi, N., Tsuzuki, M., Inoki, K., Sano, Y., Sotozono, C. & Kinoshita, S. 1338 
(2003). Successful regrafting of cultivated corneal epithelium using amniotic membrane 1339 
as a carrier in severe ocular surface disease. Cornea,  22, 70-1. 1340 
Nishida, K., Yamato, M., Hayashida, Y., Watanabe, K., Yamamoto, K., Adachi, E., Nagai, S., 1341 
Kikuchi, A., Maeda, N., Watanabe, H., Okano, T. & Tano, Y. (2004). Corneal 1342 
reconstruction with tissue- engineered cell sheets composed of autologous oral mucosal 1343 
epithelium. N Engl J Med,  351, 1187 -96. 1344 
Pellegrini, G., Traverso, C. E., Franzi, A. T., Zingirian, M., Cancedda, R. & De Luca, M. (1997). 1345 
Long- term restoration of damaged corneal surfaces with autologous cultivated corneal 1346 
epithelium. Lancet,  349, 990-3. 1347 
Prabhasawat, P., Kosrirukvongs, P., Booranapong, W. & Vajaradul, Y. (2001). Amniotic 1348 
membrane transplantation for ocular surface reconstruction. J Med Assoc Thai,  84, 705- 1349 
18. 1350 
Puangsricharern, V. & Tseng, S. C. (1995). Cytologic evidence of corneal diseases with limbal 1351 
stem cell deficiency. Ophthalmology,  102, 1476- 85. 1352 
Rama, P., Matuska, S., Paganoni, G., Spinelli, A., De Luca, M. & Pellegrini, G. (2010). Limbal 1353 
stem -cell therapy and long- term corneal regeneration. N Engl J Med,  363, 147-55. 1354 
Resnikoff, S., Pascolini, D., Mariotti, S. P. & Pokharel, G. P. (2008). Global magnitude of visual 1355 
impairment caused by uncorrected refractive errors in 2004. Bulletin of the World Health 1356 
Organization,  86, 63-70. 1357 
Sangwan, V. S., Matalia, H. P., Vemuganti, G. K., Ifthekar, G., Fatima, A., Singh, S. & Rao, G. 1358 
N. (2005). Early results of penetrating keratoplasty after cultivated limbal epithelium 1359 
transplantation. Arch Ophthalmol,  123, 334-40. 1360 
Schermer, A., Galvin, S. & Sun, T. T. (1986). Differentiation- related expression of a major 64K 1361 
corneal keratin in vivo and in culture suggests limbal location of corneal epithelial stem 1362 
cells. J Cell Biol,  103, 49-62. 1363 
Schwab, I. R., Reyes, M. & Isseroff, R. R. (2000). Successful transplantation of bioengineered 1364 
tissue replacements in patients with ocular surface disease. Cornea,  19, 421-6. 1365 
Shahdadfar, A., Haug, K., Pathak, M., Drolsum, L., Olstad, O. K., Johnsen, E. O., Petrovski, G., 1366 
Moe, M. C. & Nicolaissen, B. (2012). Ex vivo expanded autologous limbal epithelial cells 1367 
on amniotic membrane using a culture medium with human serum as single supplement. 1368 
Exp Eye Res,  97, 1-9. 1369 
Shimazaki, J., Aiba, M., Goto, E., Kato, N., Shimmura, S. & Tsubota, K. (2002). Transplantation 1370 
of human limbal epithelium cultivated on amniotic membrane for the treatment of severe 1371 
ocular surface disorders. Ophthalmology,  109, 1285- 90. 1372 
Shimazaki, J., Higa, K., Morito, F., Dogru, M., Kawakita, T., Satake, Y., Shimmura, S. & 1373 
Tsubota, K. (2007). Factors influencing outcomes in cultivated limbal epithelial 1374 
transplantation for chronic cicatricial ocular surface disorders. Am J Ophthalmol,  143, 1375 
945-53. 1376 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 40 of 51 Shortt, A. J., Secker, G. A., Notara, M. D., Limb, G. A., Khaw, P. T., Tuft, S. J. & Daniels, J. T. 1377 
(2007). Transplantation of ex vivo cultured limbal epithelial stem cells: a review of 1378 
techniques and clinical results. Surv Ophthalmol,  52, 483-502. 1379 
Smolin, G. a. T., Richard A. 2005. Smolin and Thoft’s The cornea : scientific foundations and 1380 
clinical practice , Philadelphia : Lippincott Williams & Wilkins.  1381 
Tan, D. T., Ficker, L. A. & Buckley, R. J. (1996). Limbal transplantation. Ophthalmology,  103, 1382 
29-36. 1383 
Tsai, R. J. & Tsai, R. Y. (2010). Ex vivo expansion of corneal stem cells on amniotic membrane 1384 
and their outcome. Eye Contact Lens,  36, 305-9. 1385 
Tsai, R. J. & Tseng, S. C. (1988). Substrate modulation of cultured rabbit conjunctival epithelial 1386 
cell differentiation and morphology. Invest Ophthalmol Vis Sci,  29, 1565- 76. 1387 
Tseng, S. C. (1989). Concept and application of limbal stem cells. Eye (Lond),  3 ( Pt 2) , 141-57. 1388 
Tseng, S. C. (1996). Regulation and clinical implications of corneal epithelial stem cells. Mol Biol 1389 
Rep,  23, 47-58. 1390 
Tseng, S. C., Kruse, F. E., Merritt, J. & Li, D. Q. (1996). Comparison between serum -free and 1391 
fibroblast -cocultured single- cell clonal culture systems: evidence showing that epithelial 1392 
anti-apoptotic activity is present in 3T3 fibroblast -conditioned media. Curr Eye Res,  15, 1393 
973-84. 1394 
Tseng, S. C., Meller, D., Anderson, D. F., Touhami, A., Pires, R. T., Gruterich, M., Solomon, A., 1395 
Espana, E., Sandoval, H., Ti, S. E. & Goto, E. (2002). Ex vivo preservation and 1396 
expansion of human limbal epithelial stem cells on amniotic membrane for treating 1397 
corneal diseases with total limbal stem cell deficiency. Adv Exp Med Biol,  506, 1323 -34. 1398 
Yalcindag, F. N., Incel, O. & Ozdemir, O. (2008). Effectiveness of tacrolimus in high- risk limbal 1399 
allo-graft transplantation. Ann Ophthalmol (Skokie),  40, 152-6. 1400 
Yao, Y. F., Zhang, B., Zhou, P. & Jiang, J. K. (2002). Autologous limbal grafting combined with 1401 
deep lamellar keratoplasty in unilateral eye with severe chemical or thermal burn at late 1402 
stage. Ophthalmology,  109, 2011 -7. 1403 
Zakaria, N., Koppen, C., Van Tendeloo, V., Berneman, Z., Hopkinson, A. & Tassignon, M. J. 1404 
(2010). Standardized limbal epithelial stem cell graft generation and transplantation. 1405 
Tissue Eng Part C Methods,  16, 921-7. 1406 
 1407 
 1408 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 41 of 51 14. APPENDICES 1409 
14.1.  APPENDIX I: SYMPTOM MEASUREMENT SCALES  1410 
 1411 
Ocular Surface Disease Index  (OSDI)  (Vitale et al., 2004)  1412 
 1413 
 1414 

Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 42 of 51  1415 
  1416 

Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 43 of 51  1417 
Symptom Assessment i N Dry Eye (SANDE) Questionnaire  1418 
(Schaumberg et al., 2007)  1419 
 1420 
 1421 
 1422 
 1423 
Please complete the following questions regarding the frequency and severity of your 1424 
dry eye symptoms.  1425 
 1426 
 1427 
1. Frequency of symptoms:  1428 
 1429 
Please place an ‘X’ on the line to indicate how often, on average, your eyes feel dry and/or 1430 
irritated :  1431 
 1432 
_______________________________________________ 1433 
Rarely                                                            All of the Time  1434 
 1435 
 1436 
 1437 
2. Severity of symptoms:  1438 
 1439 
Please place an ‘X’ on the line to indicate how severe, on average, your eyes feel dry and/or 1440 
irritated :  1441 
 1442 
_______________________________________________ 1443 
Very Mild                                                       Very Severe 1444 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 44 of 51 14.2.  APPENDIX II: NATIONAL EYE INSTITUTE CORNEAL FLUORESCEIN GRADING 1445 
SCALE  1446 
 1447 
 1448 
 1449 
 1450 
 1451 
For corneal fluorescein staining, saline- moistened fluorescein strips or 1% sodium fluorescein 1452 
solution will be used to stain the tear film. The entire cornea will then be examined using slit  1453 
lamp evaluation with a yellow barrier filter (#12 Wratten) and cobalt blue illumination.  Each of 1454 
five corneal zones ( superior, nasal, central, inferior, and temporal ) will be graded from 0 1455 
(normal) to 3 (severe) and total staining score of the cornea will be calculated by adding the 1456 
scores of all 5 zones together. The scores will range r from 0 to 15 points.  1457 

Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 45 of 51 14.3.  APPENDIX III: VASCULARIZATION MEASUREMENT T OOL  1458 
Digital Quantification of Neovascularization 1459 
 1460 
 1461 
 1462 
Digital slit  lamp corneal images are analyzed using graphics -editing software (Photoshop) and a 1463 
mathematical program ( Java  script  from ImageJ ).  After the total area is delineated, the blood 1464 
vessels are isolated using Photoshop.  Neovascular area is  computed using ImageJ  to measure  1465 
the area of the vessels in pixels.  1466 

Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 46 of 51 14.4.  APPENDIX IV: FANTES SCALE FOR CORNEAL OPACITY  1467 
 1468 
Grade  Description  
0 Totally clear such that no opacity could be seen by any method of slit  lamp 
microscopic examination  
0.5 A trace or a faint corneal haze seen only by indirect broad tangential illumination 
1 Haze of minimal density seen with difficulty with direct and diffuse illumination 
2 A mild haze easily visible with direct focal slit illumination  
3 A moderately dense opacity that partially obscured the iris details  
4 A severely dense opacity that obscured completely the details of intraocular 
structures  
1469 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial     PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0   Page 47 of 51 14.5.  APPENDIX V:  IMPRESSION CYTOLOGY  1470 
 1471 
 1472 
 1473 
 1474 
 1475 
 1476 
 1477 
Reporting:  1478 
 1479 
Region Goblet Cells  
Cornea 
Superior   
Inferior   
Temporal   
Nasal   
1480 

Safety and Feasibility of Cultivated Autologous Limbal Epithelial           PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0        Page 48 of 51 1 
14.6.  APPENDIX VI: SCHEDULE S OF EVENTS & PROCEDURES  FOR PARTICIPANTS COMPLETING TRANSPLANT  2 
 3 
 4 
 5 Key:  X=Donor Eye ; X=Recipient Eye ; Eye procedures marked with a black X will be performed on both the recipient and donor eyes (or the participant).  
1Perform only if needed and deemed appropriate by clinician. 2Needed only if MRSA was previously detected. 3Baseline procedures may be conducted over multiple visits after screening. 4Portions of exam/photo that require staining in recipient eye are at investigator’s discretion. 5The 
2 week, 9 month, and 15 month visits will be optional for participants for whom travel is prohibitive (see Protocol Section 6.8 for more details) .   
 
Visit 1 2 3 4 Transportation of Tissue to GMP lab and Preparation of Cell Sheets  5 6 Transportation of CALEC to Mass. Eye and Ear – Release anticipated 10 to 30 days after biopsy 7 8 9 10 11 12 13 14 15 16 17 
Time Per iod & Procedure  
(post -transplant visits timed 
from transplant date)  Screening  Baseline3 Blood draw collected within  1-7 days before  or after  biopsy  Limbal Biopsy  (Within 25 days of Baseline)  Day 1  
Post -
Biopsy  Pre-Op Corneal Reconstruction with CALEC (Day 0) – Within 24 hours of release Day 1  
Post -
Graft  Week 1 Week 25 Month 1  
(4 weeks)  Month 3   
(13 weeks)  Month 6  
(26 weeks)  Month 95 
(39 weeks)  Month  12 
 (52 weeks)  Month 155 
(65 weeks)  Month 18  
(78 weeks)  
Timing Window    Within 30 
days of 
Screening  1-2 days 
after 
biopsy  1 to 5 
days prior 
to transpl.  ±0 days  ± 3 days  ± 3 days  ± 3 days  ± 1 week  ± 1 
week  ± 1 week  ± 1 week  ± 2 week  ± 2 week  
Obtain Informed Consent  X              
Eligibility Assessment  X  X X           
Past Medical History  X X X X X X         
Pre-Op Health Screening X X             
Hematologic Lab Screening  X              
Pregnancy Tes t X   X           
Slit Lamp Examination  X X X X X4 X4 X4 X X X X X X X 
Visual Acuity BCVA  X X X X X X X X X X X X X X 
Intraocular Pressure  X X X X X X X X X X X X X X 
Fundus Examination or B -
Scan Ultrasound  X              
Schirmer’s Test  X              
AS-OCT   X          X  X 
IVCM   X          X  X 
Slit Lamp Photo s  X X X  X4 X4 X4 X X X X X X X 
Conjunctival Swab & Culture  X        X2   X2   
Impression Cytology1            X1 X1 X1 
Punctal Plugs1 X X X X X X X X X X X X X X 
Bandage Contact Lens1     X X X X X X X X X X 
Antibiotic   X X X X X X X1 X1 X1 X1 X1 X1 
Topical steroid  and 
fluoroquinolone    X X X X X X X1 X1 X1 X1 X1 X1 
Vancomycin2  X X X X X X X X1 X1 X1 X1 X1 X1 
Artificial Tears     X X X X X X X X X X 
20% Autologous Serum Drops      X X X X1 X1 X1 X1 X1 X1 X1 
Symptom Assessment   X       X X X X X X 
Adverse Event Assessment   X (changes 
in medical 
status)   
X X X X X X X X X X X X 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial          
 PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0      
  Page 49 of 51  1486 
 1487 
15. PROTOCOL ADDENDUM: SECOND TRANSPLANT   1488 
 1489 
15.1.  OVERVIEW   1490 
Some study participants who received CALEC and for whom epithelial defect and conjunctivalization 1491 
has not resolved after 12 months may benefit from an additional transplant.  Participants meeting study 1492 
criteria (section 15.3) may be offered the opportunity to undergo a second procedure, either CALEC or 1493 
CLAU.  The following chapter outlines the protocol that will be followed for these participants. Up to 1494 
three participants can receive a second transplant.  1495 
 1496 
15.2.  CRITERIA FOR SECOND TRANSPLANT  1497 
All of the following criteria must be met in order for a participant to be considered for a second 1498 
transplant.  1499 
• Participant previously received CALEC (participants previously receiving CLAU will not be 1500 
eligible)  1501 
• Second transplant cannot occur prior to the 12- month visit  1502 
• Presence of epithelial defect in recipient eye  1503 
• Must have been present at 2 or more visits (>1 month between visits), any time on or after 1504 
the 3- month visit  1505 
• >1 mm in any dimension  1506 
• (Note: Does not need to be present at the Screening/Baseline visit prior to second 1507 
transplant)  1508 
• Presence of conjunctivalization / fibrovascular pannus in recipient eye 1509 
• Must be present at the Screening/Baseline visit prior to second transplant  1510 
• >2 mm from the limbus  1511 
• ≥6 clock hours  1512 
• Investigator discretion that repeat transplant has therapeutic potential  1513 
• Absence of the following in the donor eye:  1514 
• Conjunctivalization of the cornea defined by fibrovascular pannus more than 2mm from 1515 
the limbus into the cornea for ≥3 clock hours  1516 
• Lack of limbal palisades of Vogt for ≥3 clock hours  1517 
• History of allo -limbal transplantation  1518 
 1519 
NOTE: these criteria are independent of whether the participant meets the protocol definition of 1520 
complete or partial success.  1521 
 1522 
15.3.  INFORMED CONSENT PROCESS  1523 
Participants meeting criteria and offered a second transplant option will undergo an informed consent 1524 
process.  The informed consent process will include a discussion with participants that they have the 1525 
option of CLAU, CALEC, or no second transplant.  1526 
 1527 
15.4.  SCREENING AND BASELINE  1528 
Participants consenting to undergo a second transplant, either CLAU or CALEC, will undergo the same 1529 
screening and baseline procedures in the protocol for the initial CALEC transplant (section 6.8.1- 6.8.2), 1530 
with the following exceptions:   1531 
• The screening visit will be combined with baseline visit since the subjects receiving the second 1532 
graft will have already been followed for at least a year since their initial CALEC transplant  1533 
• The combined screening/baseline visit will include the following:  1534 
o Evaluation of eligibility for a second graft  1535 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial          
 PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0      
  Page 50 of 51 o Hematologic lab screening will include only the blood draw collected within 1- 7 days as 1536 
required for manufacturing of the graft per DCDI protocol  1537 
 Hepatitis B   1538 
 Hepatitis C  1539 
 HIV  1540 
o Slit lamp exam  1541 
o BCVA  1542 
o IOP 1543 
o Fundus exam or B -scan 1544 
o AS-OCT  1545 
o IVCM  1546 
o Slit lamp photos  1547 
o Symptom assessment  1548 
o Conjunctival swab and culture   1549 
 (if MRSA positive, the original protocol will be followed for vancomycin)  1550 
o Schirmer’s test (optional)  1551 
o Punctal plus (optional)  1552 
The visit will not require punctal plugs, bandage contact lenses, prednisolone, vancomycin, 1553 
preservative- free tears and autologous  1554 
serum tears as participants will already be using them as treatments from initial CALEC. The 1555 
preoperative antibiotic drop will be given prior to the biopsy and transplant in the respective operative 1556 
eyes, as with the initial CALEC (section 6.2.1). The Schirmer test may not be needed as participants 1557 
would have had it to receive the initial CALEC and would have had plugs if necessary.  . The full set of 1558 
labs will not be repeated as they would have been done to enter the study for the initial CALEC. The 1559 
labs that are required for manufacturing of CALEC will be repeated as noted above, for participants 1560 
pursuing second CALEC transplant.    1561 
 1562 
15.5.  BIOPSY AND TRANSPLANT  1563 
 1564 
For participants choosing to undergo CLAU  1565 
 The pre- operative visit will occur within 60 days after baseline and within 1- 5 days prior to 1566 
transplant, and testing will include slit lamp exam, visual acuity, IOP.  1567 
 The biopsy and transplant procedures and subsequent medication regimens will follow standard 1568 
care.   1569 
 1570 
For participants choosing to undergo CALEC  1571 
 The post -biopsy and pre- operative visits and testing schedule, including all procedures and 1572 
measurements, will be the same as the current protocol (APPENDIX VI).  1573 
 The CALEC manufacturing (section 6.1), biopsy and transplant procedures (section 6.2) and 1574 
subsequent medication regimens (section 6.5) will follow the protocol for initial CALEC  1575 
 If a participant experiences failure of the biopsy to generate a viable cell sheet, the participant 1576 
will not be eligible to rescreen for another biopsy attempt.  The participant will be monitored by 1577 
the study team for 30 days to check for any adverse events related to the biopsy procedures.   If 1578 
the donor eye has a complication or adverse event that does not resolve after 30 days, the study 1579 
team will continue to monitor until it resolves.  The participant will discontinue the study after the 1580 
monitoring period.  1581 
Safety and Feasibility of Cultivated Autologous Limbal Epithelial          
 PI: Ula Jurkunas, M D 
Cell Transplantation in the Treatment  of Limbal Stem Cell Deficiency  
CALEC Protocol_Feb 8 2022 _v6.0      
  Page 51 of 51   1582 
 1583 
15.6.  STUDY PROCEDURES, MEASUREMENTS, AND VISIT SCHEDULE  1584 
 1585 
For all participants choosing to undergo a second transplant (either CALEC or CLAU), the post - 1586 
operative visit and testing schedule, including all procedures, measurements and data collection, will be 1587 
the same as the current protocol (APPENDIX VI).  The protocol schedule will be followed until a 1588 
common study closeout date is reached.       1589 
 1590 
15.7.  ANALYSIS CONSIDERATIONS  1591 
15.7.1.  SAFETY  1592 
 Safety events of interest, as defined in section 7.1.1.:     1593 
o Primary safety analysis for protocol objective:  Safety events will only be tabulated up 1594 
to (not including) the date of the biopsy for the second CALEC or CLAU transplant.  1595 
o A dditional analysis evaluating second CALEC transplant : Safety events following the 1596 
biopsy for the second CALEC transplant will be summarized separately.   1597 
 1598 
15.7.2.  FEASIBILITY  1599 
 Feasibility measures, as defined in section 7.1.2.:   1600 
o Primary feasibility analysis for protocol objective:  The biopsy attempts for only the 1601 
initial CALEC transplants will be included in the primary feasibility outcome calculation of 1602 
feasibility success  1603 
o A dditional analysis evaluating second CALEC transplant:  The biopsy attempts for 1604 
second CALEC transplant will be summarized separately  1605 
  1606 
15.7.3.  EFFICACY  1607 
 Efficacy outcome measures, as defined in section 7.2, will be evaluated the following 1608 
ways:  1609 
o Primary efficacy analysis for protocol objective:  Efficacy outcome data will only be 1610 
included up to (not including) the date of biopsy for the second CALEC or CLAU 1611 
transplant  1612 
o A dditional analyses evaluating second CALEC transplant :  1613 
 Efficacy outcome data will be evaluated relative to original baseline through the 1614 
latest protocol visit prior to the study closeout date.  1615 
 Efficacy outcome data will be evaluated relative to second CALEC baseline 1616 
through the latest protocol visit prior to the study closeout date.  1617 
 1618 